WO2023070501A1 - Personal cleansing composition with an organic acid having a pka greater than 2.7 - Google Patents
Personal cleansing composition with an organic acid having a pka greater than 2.7 Download PDFInfo
- Publication number
- WO2023070501A1 WO2023070501A1 PCT/CN2021/127315 CN2021127315W WO2023070501A1 WO 2023070501 A1 WO2023070501 A1 WO 2023070501A1 CN 2021127315 W CN2021127315 W CN 2021127315W WO 2023070501 A1 WO2023070501 A1 WO 2023070501A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- personal cleansing
- acid
- cleansing composition
- composition
- surfactants
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 292
- 150000007524 organic acids Chemical class 0.000 title claims abstract description 39
- 239000011734 sodium Substances 0.000 claims abstract description 61
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 61
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 60
- 239000003945 anionic surfactant Substances 0.000 claims abstract description 53
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 claims abstract description 38
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 238000007046 ethoxylation reaction Methods 0.000 claims abstract description 15
- 239000004094 surface-active agent Substances 0.000 claims description 62
- -1 glucose carboxylate Chemical class 0.000 claims description 38
- 241000894006 Bacteria Species 0.000 claims description 33
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 33
- 229930195712 glutamate Natural products 0.000 claims description 30
- 230000000845 anti-microbial effect Effects 0.000 claims description 26
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 23
- QNAYBMKLOCPYGJ-UHFFFAOYSA-M alaninate Chemical compound CC(N)C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-M 0.000 claims description 21
- 241000191967 Staphylococcus aureus Species 0.000 claims description 20
- ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 claims description 20
- ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical compound OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims description 16
- 229960003237 betaine Drugs 0.000 claims description 16
- 229940071089 sarcosinate Drugs 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 12
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 12
- 239000004064 cosurfactant Substances 0.000 claims description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000002888 zwitterionic surfactant Substances 0.000 claims description 12
- 239000004599 antimicrobial Substances 0.000 claims description 11
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims description 11
- 108700004121 sarkosyl Proteins 0.000 claims description 11
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 claims description 11
- 229940045885 sodium lauroyl sarcosinate Drugs 0.000 claims description 11
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 claims description 10
- 230000004040 defense response to microbe Effects 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 8
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 7
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 7
- 239000002280 amphoteric surfactant Substances 0.000 claims description 7
- 229940073507 cocamidopropyl betaine Drugs 0.000 claims description 7
- 239000001630 malic acid Substances 0.000 claims description 7
- 235000011090 malic acid Nutrition 0.000 claims description 7
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 6
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 6
- 239000001361 adipic acid Substances 0.000 claims description 6
- 235000011037 adipic acid Nutrition 0.000 claims description 6
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 6
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 6
- 239000004310 lactic acid Substances 0.000 claims description 6
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- 229940104261 taurate Drugs 0.000 claims description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- IXOCGRPBILEGOX-UHFFFAOYSA-N 3-[3-(dodecanoylamino)propyl-dimethylazaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O IXOCGRPBILEGOX-UHFFFAOYSA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 claims description 4
- 239000005711 Benzoic acid Substances 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 235000010233 benzoic acid Nutrition 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 3
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- MRUAUOIMASANKQ-UHFFFAOYSA-O carboxymethyl-[3-(dodecanoylamino)propyl]-dimethylazanium Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(O)=O MRUAUOIMASANKQ-UHFFFAOYSA-O 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000000174 gluconic acid Substances 0.000 claims description 3
- 235000012208 gluconic acid Nutrition 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 229940075468 lauramidopropyl betaine Drugs 0.000 claims description 3
- AGGIJOLULBJGTQ-UHFFFAOYSA-N sulfoacetic acid Chemical compound OC(=O)CS(O)(=O)=O AGGIJOLULBJGTQ-UHFFFAOYSA-N 0.000 claims description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 241000195940 Bryophyta Species 0.000 claims description 2
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 claims description 2
- 238000005187 foaming Methods 0.000 claims description 2
- 235000012209 glucono delta-lactone Nutrition 0.000 claims description 2
- 229960003681 gluconolactone Drugs 0.000 claims description 2
- 235000011929 mousse Nutrition 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 description 167
- 229940083542 sodium Drugs 0.000 description 57
- 238000001514 detection method Methods 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 239000010410 layer Substances 0.000 description 27
- 239000000047 product Substances 0.000 description 26
- 238000012360 testing method Methods 0.000 description 23
- 238000000034 method Methods 0.000 description 22
- 239000000523 sample Substances 0.000 description 21
- 239000004615 ingredient Substances 0.000 description 20
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 16
- 239000003205 fragrance Substances 0.000 description 14
- 230000037125 natural defense Effects 0.000 description 14
- 238000005259 measurement Methods 0.000 description 12
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 11
- 230000004888 barrier function Effects 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 238000005070 sampling Methods 0.000 description 11
- 210000000245 forearm Anatomy 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 241000209140 Triticum Species 0.000 description 9
- 235000021307 Triticum Nutrition 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000002390 adhesive tape Substances 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 238000001139 pH measurement Methods 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000006150 trypticase soy agar Substances 0.000 description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- 108010077895 Sarcosine Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940071124 cocoyl glutamate Drugs 0.000 description 6
- 239000003906 humectant Substances 0.000 description 6
- 239000011591 potassium Substances 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- JOLYVEWZEPKDIJ-UTLKBRERSA-L dipotassium;(2s)-2-(dodecanoylamino)pentanedioate Chemical compound [K+].[K+].CCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CCC([O-])=O JOLYVEWZEPKDIJ-UTLKBRERSA-L 0.000 description 4
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 4
- HWUINYGRRJTXGE-UTLKBRERSA-L disodium;(2s)-2-(dodecanoylamino)pentanedioate Chemical compound [Na+].[Na+].CCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CCC([O-])=O HWUINYGRRJTXGE-UTLKBRERSA-L 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 229940071145 lauroyl sarcosinate Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 4
- 229940081510 piroctone olamine Drugs 0.000 description 4
- 230000008591 skin barrier function Effects 0.000 description 4
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 4
- 239000004299 sodium benzoate Substances 0.000 description 4
- 235000010234 sodium benzoate Nutrition 0.000 description 4
- 239000003760 tallow Substances 0.000 description 4
- 239000001974 tryptic soy broth Substances 0.000 description 4
- 108010050327 trypticase-soy broth Proteins 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- JPMIIZHYYWMHDT-UHFFFAOYSA-N octhilinone Chemical compound CCCCCCCCN1SC=CC1=O JPMIIZHYYWMHDT-UHFFFAOYSA-N 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- RTVVXRKGQRRXFJ-UHFFFAOYSA-N sodium;2-sulfobutanedioic acid Chemical compound [Na].OC(=O)CC(C(O)=O)S(O)(=O)=O RTVVXRKGQRRXFJ-UHFFFAOYSA-N 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- TUBPSFQENHCYBW-HVDRVSQOSA-N (2s)-2-aminopentanedioic acid;2-[bis(2-hydroxyethyl)amino]ethanol Chemical compound OC(=O)[C@@H](N)CCC(O)=O.OCCN(CCO)CCO TUBPSFQENHCYBW-HVDRVSQOSA-N 0.000 description 2
- MJGBOFOZSAEULI-DFWYDOINSA-N (2s)-5-oxopyrrolidine-2-carboxylic acid;5-oxopyrrolidine-2-carboxylic acid Chemical compound OC(=O)C1CCC(=O)N1.OC(=O)[C@@H]1CCC(=O)N1 MJGBOFOZSAEULI-DFWYDOINSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- ACCAIGJKLCJFHP-UQKRIMTDSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;(2s)-2-(dodecanoylamino)pentanedioic acid Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCC(O)=O ACCAIGJKLCJFHP-UQKRIMTDSA-N 0.000 description 2
- BEABHZRODBBUAU-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;2-(methylamino)acetic acid Chemical compound CNCC(O)=O.OCCN(CCO)CCO BEABHZRODBBUAU-UHFFFAOYSA-N 0.000 description 2
- FUUGOUJDTGRGMR-GMFCBQQYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;2-[methyl-[(z)-octadec-9-enoyl]amino]acetic acid Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(=O)N(C)CC(O)=O FUUGOUJDTGRGMR-GMFCBQQYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 240000007436 Cananga odorata Species 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- GNMAJAFGCGXYGH-ZOWNYOTGSA-M N[C@@H](CCC(=O)[O-])C(=O)OC(CCCCCCCCC=C)=O.[Na+] Chemical compound N[C@@H](CCC(=O)[O-])C(=O)OC(CCCCCCCCC=C)=O.[Na+] GNMAJAFGCGXYGH-ZOWNYOTGSA-M 0.000 description 2
- ACAXXPXMEBRGLB-IZHYLRJQSA-L N[C@@H](CCC(=O)[O-])C(=O)OC(CCCCCCCCC=C)=O.[Na+].[Na+].C(CCCCCCCCC=C)(=O)OC([C@@H](N)CCC(=O)[O-])=O Chemical compound N[C@@H](CCC(=O)[O-])C(=O)OC(CCCCCCCCC=C)=O.[Na+].[Na+].C(CCCCCCCCC=C)(=O)OC([C@@H](N)CCC(=O)[O-])=O ACAXXPXMEBRGLB-IZHYLRJQSA-L 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- HAMGNFFXQJOFRZ-UHFFFAOYSA-L aluminum;zirconium(4+);chloride;hydroxide;hydrate Chemical compound O.[OH-].[Al+3].[Cl-].[Zr+4] HAMGNFFXQJOFRZ-UHFFFAOYSA-L 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- OCSIXPGPUXCISD-UHFFFAOYSA-N azane;2-[dodecanoyl(methyl)amino]acetic acid Chemical compound N.CCCCCCCCCCCC(=O)N(C)CC(O)=O OCSIXPGPUXCISD-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- DRTBPCASGTVPLF-VWLOTQADSA-N didodecanoyl (2s)-2-aminopentanedioate Chemical compound CCCCCCCCCCCC(=O)OC(=O)CC[C@H](N)C(=O)OC(=O)CCCCCCCCCCC DRTBPCASGTVPLF-VWLOTQADSA-N 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- YWGWUEXUIOPNMW-FJSYBICCSA-L dipotassium;(2s)-2-(octadecanoylamino)pentanedioate Chemical compound [K+].[K+].CCCCCCCCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CCC([O-])=O YWGWUEXUIOPNMW-FJSYBICCSA-L 0.000 description 2
- TWRWROOHGNQOQC-XRIOVQLTSA-L dipotassium;(2s)-2-(octanoylamino)pentanedioate Chemical compound [K+].[K+].CCCCCCCC(=O)N[C@H](C([O-])=O)CCC([O-])=O TWRWROOHGNQOQC-XRIOVQLTSA-L 0.000 description 2
- IKNWNODSTRNMLD-SQKCAUCHSA-L dipotassium;(2s)-2-(tetradecanoylamino)pentanedioate Chemical compound [K+].[K+].CCCCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CCC([O-])=O IKNWNODSTRNMLD-SQKCAUCHSA-L 0.000 description 2
- ACNAFCGCINVEDL-GXKRWWSZSA-L dipotassium;(2s)-2-(undec-10-enoylamino)pentanedioate Chemical compound [K+].[K+].[O-]C(=O)CC[C@@H](C([O-])=O)NC(=O)CCCCCCCCC=C ACNAFCGCINVEDL-GXKRWWSZSA-L 0.000 description 2
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 2
- 229940079779 disodium cocoyl glutamate Drugs 0.000 description 2
- 229940047038 disodium myristoyl glutamate Drugs 0.000 description 2
- 229940079784 disodium stearoyl glutamate Drugs 0.000 description 2
- WODOUQLMOIMKAL-FJSYBICCSA-L disodium;(2s)-2-(octadecanoylamino)pentanedioate Chemical compound [Na+].[Na+].CCCCCCCCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CCC([O-])=O WODOUQLMOIMKAL-FJSYBICCSA-L 0.000 description 2
- JRHWWJSWHFFZRY-XRIOVQLTSA-L disodium;(2s)-2-(octanoylamino)pentanedioate Chemical compound [Na+].[Na+].CCCCCCCC(=O)N[C@H](C([O-])=O)CCC([O-])=O JRHWWJSWHFFZRY-XRIOVQLTSA-L 0.000 description 2
- SXBBFOVRSQCYFE-SQKCAUCHSA-L disodium;(2s)-2-(tetradecanoylamino)pentanedioate Chemical compound [Na+].[Na+].CCCCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CCC([O-])=O SXBBFOVRSQCYFE-SQKCAUCHSA-L 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 229940049906 glutamate Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 229940115478 isopropyl lauroyl sarcosinate Drugs 0.000 description 2
- 229940001447 lactate Drugs 0.000 description 2
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000012263 liquid product Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 229940082006 potassium cocoyl glutamate Drugs 0.000 description 2
- 229940099874 potassium lauroyl glutamate Drugs 0.000 description 2
- RJLXQRRDQRGFJR-ZOWNYOTGSA-M potassium;(2s)-5-hydroxy-5-oxo-2-(undec-10-enoylamino)pentanoate Chemical compound [K+].OC(=O)CC[C@@H](C([O-])=O)NC(=O)CCCCCCCCC=C RJLXQRRDQRGFJR-ZOWNYOTGSA-M 0.000 description 2
- KCQOKZAQSWTPIL-BDQAORGHSA-M potassium;(4s)-5-hydroxy-4-(octadecanoylamino)-5-oxopentanoate Chemical compound [H+].[K+].CCCCCCCCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CCC([O-])=O KCQOKZAQSWTPIL-BDQAORGHSA-M 0.000 description 2
- WONHSIFWFDNSCE-PPHPATTJSA-M potassium;(4s)-5-hydroxy-4-(octanoylamino)-5-oxopentanoate Chemical compound [H+].[K+].CCCCCCCC(=O)N[C@H](C([O-])=O)CCC([O-])=O WONHSIFWFDNSCE-PPHPATTJSA-M 0.000 description 2
- KYLDDUZJZSKJER-NTISSMGPSA-M potassium;(4s)-5-hydroxy-5-oxo-4-(tetradecanoylamino)pentanoate Chemical compound [H+].[K+].CCCCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CCC([O-])=O KYLDDUZJZSKJER-NTISSMGPSA-M 0.000 description 2
- JEMLSRUODAIULV-UHFFFAOYSA-M potassium;2-[dodecanoyl(methyl)amino]acetate Chemical compound [K+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O JEMLSRUODAIULV-UHFFFAOYSA-M 0.000 description 2
- XLCIFRJORZNGEV-UHFFFAOYSA-N propan-2-yl 2-[dodecanoyl(methyl)amino]acetate Chemical compound CCCCCCCCCCCC(=O)N(C)CC(=O)OC(C)C XLCIFRJORZNGEV-UHFFFAOYSA-N 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 229940079781 sodium cocoyl glutamate Drugs 0.000 description 2
- 229940057950 sodium laureth sulfate Drugs 0.000 description 2
- 229940045944 sodium lauroyl glutamate Drugs 0.000 description 2
- 229940048109 sodium methyl cocoyl taurate Drugs 0.000 description 2
- 229940077092 sodium myristoyl glutamate Drugs 0.000 description 2
- 229940060304 sodium myristoyl sarcosinate Drugs 0.000 description 2
- 229940045898 sodium stearoyl glutamate Drugs 0.000 description 2
- LFUXMTKAILZVTA-ZOWNYOTGSA-M sodium;(2s)-2-(dodecanoylamino)propanoate Chemical compound [Na+].CCCCCCCCCCCC(=O)N[C@@H](C)C([O-])=O LFUXMTKAILZVTA-ZOWNYOTGSA-M 0.000 description 2
- FCBUGCHAVCFTHW-NTISSMGPSA-N sodium;(2s)-2-(tetradecanoylamino)pentanedioic acid Chemical compound [Na].CCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCC(O)=O FCBUGCHAVCFTHW-NTISSMGPSA-N 0.000 description 2
- KLIFRVSZGDONER-FERBBOLQSA-M sodium;(4s)-4-(hexadecanoylamino)-5-hydroxy-5-oxopentanoate Chemical compound [H+].[Na+].CCCCCCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CCC([O-])=O KLIFRVSZGDONER-FERBBOLQSA-M 0.000 description 2
- KDHFCTLPQJQDQI-BDQAORGHSA-M sodium;(4s)-4-amino-5-octadecanoyloxy-5-oxopentanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCC([O-])=O KDHFCTLPQJQDQI-BDQAORGHSA-M 0.000 description 2
- BCGXTKYOBWQPCN-PPHPATTJSA-M sodium;(4s)-5-hydroxy-4-(octanoylamino)-5-oxopentanoate Chemical compound [H+].[Na+].CCCCCCCC(=O)N[C@H](C([O-])=O)CCC([O-])=O BCGXTKYOBWQPCN-PPHPATTJSA-M 0.000 description 2
- IKGKWKGYFJBGQJ-UHFFFAOYSA-M sodium;2-(dodecanoylamino)acetate Chemical compound [Na+].CCCCCCCCCCCC(=O)NCC([O-])=O IKGKWKGYFJBGQJ-UHFFFAOYSA-M 0.000 description 2
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 2
- CAVXVRQDZKMZDB-UHFFFAOYSA-M sodium;2-[dodecanoyl(methyl)amino]ethanesulfonate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CCS([O-])(=O)=O CAVXVRQDZKMZDB-UHFFFAOYSA-M 0.000 description 2
- AUHKUMFBHOJIMU-UHFFFAOYSA-M sodium;2-[hexadecanoyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCCCCC(=O)N(C)CC([O-])=O AUHKUMFBHOJIMU-UHFFFAOYSA-M 0.000 description 2
- KHCOJQDJOCNUGV-UHFFFAOYSA-M sodium;2-[methyl(tetradecanoyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCCC(=O)N(C)CC([O-])=O KHCOJQDJOCNUGV-UHFFFAOYSA-M 0.000 description 2
- VLKIFCBXANYYCK-GMFCBQQYSA-M sodium;2-[methyl-[(z)-octadec-9-enoyl]amino]acetate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(=O)N(C)CC([O-])=O VLKIFCBXANYYCK-GMFCBQQYSA-M 0.000 description 2
- IZWPGJFSBABFGL-GMFCBQQYSA-M sodium;2-[methyl-[(z)-octadec-9-enoyl]amino]ethanesulfonate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(=O)N(C)CCS([O-])(=O)=O IZWPGJFSBABFGL-GMFCBQQYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- DIORMHZUUKOISG-UHFFFAOYSA-N sulfoformic acid Chemical compound OC(=O)S(O)(=O)=O DIORMHZUUKOISG-UHFFFAOYSA-N 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229940048912 triethanolamine cocoyl glutamate Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- AMRBZKOCOOPYNY-QXMHVHEDSA-N 2-[dimethyl-[(z)-octadec-9-enyl]azaniumyl]acetate Chemical compound CCCCCCCC\C=C/CCCCCCCC[N+](C)(C)CC([O-])=O AMRBZKOCOOPYNY-QXMHVHEDSA-N 0.000 description 1
- HJDITXMCJQRQLU-UHFFFAOYSA-N 2-[dodecanoyl(methyl)amino]acetate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCC(=O)N(C)CC(O)=O HJDITXMCJQRQLU-UHFFFAOYSA-N 0.000 description 1
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- WQPMYSHJKXVTME-UHFFFAOYSA-N 3-hydroxypropane-1-sulfonic acid Chemical compound OCCCS(O)(=O)=O WQPMYSHJKXVTME-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- IBYCEACZVUOBIV-UHFFFAOYSA-N 4-methylpentyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCC(C)C IBYCEACZVUOBIV-UHFFFAOYSA-N 0.000 description 1
- AUGIYYGVQDZOLU-UHFFFAOYSA-N 4-methylpentyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCC(C)C AUGIYYGVQDZOLU-UHFFFAOYSA-N 0.000 description 1
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- ODMZDMMTKHXXKA-QXMHVHEDSA-N 8-methylnonyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCCCCCCC(C)C ODMZDMMTKHXXKA-QXMHVHEDSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 235000007571 Cananga odorata Nutrition 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- QNWXFZWISDPYRL-UHFFFAOYSA-L [Na+].[Mg+2].[O-]C(=O)CCC([O-])=O Chemical compound [Na+].[Mg+2].[O-]C(=O)CCC([O-])=O QNWXFZWISDPYRL-UHFFFAOYSA-L 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229960001040 ammonium chloride Drugs 0.000 description 1
- 229940098323 ammonium cocoyl isethionate Drugs 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 229940010556 ammonium phosphate Drugs 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- VDXDJNXCULYUIU-UHFFFAOYSA-N azane 2-dodecoxy-2-oxoethanesulfonic acid Chemical compound N.CCCCCCCCCCCCOC(=O)CS(O)(=O)=O VDXDJNXCULYUIU-UHFFFAOYSA-N 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- PPOZILIWLOFYOG-UHFFFAOYSA-N bis(2-hexyldecyl) hexanedioate Chemical compound CCCCCCCCC(CCCCCC)COC(=O)CCCCC(=O)OCC(CCCCCC)CCCCCCCC PPOZILIWLOFYOG-UHFFFAOYSA-N 0.000 description 1
- IUGNTDSUZLPSOK-UHFFFAOYSA-N bis(4-methylpentyl) hexanedioate Chemical compound CC(C)CCCOC(=O)CCCCC(=O)OCCCC(C)C IUGNTDSUZLPSOK-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940048851 cetyl ricinoleate Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 229940096362 cocoamphoacetate Drugs 0.000 description 1
- 229940047648 cocoamphodiacetate Drugs 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940073499 decyl glucoside Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KBODESQIOVVMAI-UHFFFAOYSA-N decyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCC KBODESQIOVVMAI-UHFFFAOYSA-N 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- LVYZJEPLMYTTGH-UHFFFAOYSA-H dialuminum chloride pentahydroxide dihydrate Chemical compound [Cl-].[Al+3].[OH-].[OH-].[Al+3].[OH-].[OH-].[OH-].O.O LVYZJEPLMYTTGH-UHFFFAOYSA-H 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- SHLKYEAQGUCTIO-UHFFFAOYSA-N diazanium;4-dodecoxy-4-oxo-3-sulfobutanoate Chemical compound [NH4+].[NH4+].CCCCCCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O.CCCCCCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O SHLKYEAQGUCTIO-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 229940031569 diisopropyl sebacate Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229940079868 disodium laureth sulfosuccinate Drugs 0.000 description 1
- 229940079886 disodium lauryl sulfosuccinate Drugs 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- QKQCPXJIOJLHAL-UHFFFAOYSA-L disodium;2-[2-(carboxylatomethoxy)ethyl-[2-(dodecanoylamino)ethyl]amino]acetate Chemical compound [Na+].[Na+].CCCCCCCCCCCC(=O)NCCN(CC([O-])=O)CCOCC([O-])=O QKQCPXJIOJLHAL-UHFFFAOYSA-L 0.000 description 1
- GLSRFBDXBWZNLH-UHFFFAOYSA-L disodium;2-chloroacetate;2-(4,5-dihydroimidazol-1-yl)ethanol;hydroxide Chemical compound [OH-].[Na+].[Na+].[O-]C(=O)CCl.OCCN1CCN=C1 GLSRFBDXBWZNLH-UHFFFAOYSA-L 0.000 description 1
- YGAXLGGEEQLLKV-UHFFFAOYSA-L disodium;4-dodecoxy-4-oxo-2-sulfonatobutanoate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOC(=O)CC(C([O-])=O)S([O-])(=O)=O YGAXLGGEEQLLKV-UHFFFAOYSA-L 0.000 description 1
- KHIQYZGEUSTKSB-UHFFFAOYSA-L disodium;4-dodecoxy-4-oxo-3-sulfobutanoate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O.CCCCCCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O KHIQYZGEUSTKSB-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- XAMHKORMKJIEFW-AYTKPMRMSA-N hexadecyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/C[C@H](O)CCCCCC XAMHKORMKJIEFW-AYTKPMRMSA-N 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 description 1
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940093629 isopropyl isostearate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 229940048866 lauramine oxide Drugs 0.000 description 1
- 229940071188 lauroamphodiacetate Drugs 0.000 description 1
- 229940094506 lauryl betaine Drugs 0.000 description 1
- 229940048848 lauryl glucoside Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 229910000400 magnesium phosphate tribasic Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- BPLYVSYSBPLDOA-GYOJGHLZSA-N n-[(2r,3r)-1,3-dihydroxyoctadecan-2-yl]tetracosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H](CO)[C@H](O)CCCCCCCCCCCCCCC BPLYVSYSBPLDOA-GYOJGHLZSA-N 0.000 description 1
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000037070 skin defense Effects 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940096501 sodium cocoamphoacetate Drugs 0.000 description 1
- 229940065859 sodium cocoyl glycinate Drugs 0.000 description 1
- 229940079776 sodium cocoyl isethionate Drugs 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical group [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 229940045998 sodium isethionate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229940048106 sodium lauroyl isethionate Drugs 0.000 description 1
- 229940007636 sodium lauroyl methyl isethionate Drugs 0.000 description 1
- 229940079862 sodium lauryl sarcosinate Drugs 0.000 description 1
- 229940075560 sodium lauryl sulfoacetate Drugs 0.000 description 1
- 229940045888 sodium myristoyl isethionate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229940045919 sodium polymetaphosphate Drugs 0.000 description 1
- 235000019832 sodium triphosphate Nutrition 0.000 description 1
- SLBXZQMMERXQAL-UHFFFAOYSA-M sodium;1-dodecoxy-4-hydroxy-1,4-dioxobutane-2-sulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O SLBXZQMMERXQAL-UHFFFAOYSA-M 0.000 description 1
- NTYZDAJPNNBYED-UHFFFAOYSA-M sodium;2-(2-dodecanoyloxypropanoyloxy)propanoate Chemical compound [Na+].CCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O NTYZDAJPNNBYED-UHFFFAOYSA-M 0.000 description 1
- MCFLGJDKSROECH-KVVVOXFISA-M sodium;2-[(z)-octadec-9-enoyl]oxyethanesulfonate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(=O)OCCS([O-])(=O)=O MCFLGJDKSROECH-KVVVOXFISA-M 0.000 description 1
- HVFAVOFILADWEZ-UHFFFAOYSA-M sodium;2-[2-(dodecanoylamino)ethyl-(2-hydroxyethyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCC(=O)NCCN(CCO)CC([O-])=O HVFAVOFILADWEZ-UHFFFAOYSA-M 0.000 description 1
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 1
- HYHAWELIVMOSBT-UHFFFAOYSA-M sodium;2-aminopentadecanoate Chemical compound [Na+].CCCCCCCCCCCCCC(N)C([O-])=O HYHAWELIVMOSBT-UHFFFAOYSA-M 0.000 description 1
- BRMSVEGRHOZCAM-UHFFFAOYSA-M sodium;2-dodecanoyloxyethanesulfonate Chemical compound [Na+].CCCCCCCCCCCC(=O)OCCS([O-])(=O)=O BRMSVEGRHOZCAM-UHFFFAOYSA-M 0.000 description 1
- NVIZQHFCDBQNPH-UHFFFAOYSA-M sodium;2-dodecanoyloxypropane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCC(=O)OC(C)CS([O-])(=O)=O NVIZQHFCDBQNPH-UHFFFAOYSA-M 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- LADXKQRVAFSPTR-UHFFFAOYSA-M sodium;2-hydroxyethanesulfonate Chemical compound [Na+].OCCS([O-])(=O)=O LADXKQRVAFSPTR-UHFFFAOYSA-M 0.000 description 1
- WEXQJKLTLYEHLQ-UHFFFAOYSA-M sodium;2-tetradecanoyloxyethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCCC(=O)OCCS([O-])(=O)=O WEXQJKLTLYEHLQ-UHFFFAOYSA-M 0.000 description 1
- IWMMSZLFZZPTJY-UHFFFAOYSA-M sodium;3-(dodecylamino)propane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCNCCCS([O-])(=O)=O IWMMSZLFZZPTJY-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
Abstract
A personal cleansing composition includes from 1% to 15% of an anionic surfactant by weight of the composition, wherein the anionic surfactant comprises sodium laureth (n) sulfate SLEnS, wherein n is the average moles of ethoxylation, wherein n equals to 1, 2 or 3; from 0.01% to 1% of an organic acid having a pKa greater than 2.7, or a cosmetically acceptable salt thereof, or a mixture thereof, by weight of the composition; and wherein the pH of the personal cleansing composition is from 5.0 to 6.5.
Description
The present application generally relates to personal cleansing compositions, their methods for improving or maintaining the natural defensive ability of human skin against bacteria, in particular Staphylococcus aureus, and their uses. The personal cleansing compositions have desirable properties for helping skin maintain or improve its natural barrier against bacteria, and retaining moisture due to the use of an organic acid having a pKa greater than about 2.7 at a certain pH from about 5.0 to about 6.5.
Personal cleansing compositions have been traditionally marketed in a variety of forms such as bar soaps, creams, lotions, and gels. Typically, these products need to satisfy a number of criteria to be acceptable to consumers. These criteria include cleansing effectiveness, skin feel, mildness to skin, hair, and ocular mucosae, and lather volume. Ideal personal cleansers should gently cleanse the skin or hair, cause little or no irritation, and should not leave the skin or hair overly dry after frequent use.
Skin provides the first line of defense against bacteria and fungi. Healthy skin contains natural moisturizing factors (NMF) . In addition to helping skin retain moisture, NMF can also act as a buffer that can help skin retain its acid mantle. The acid mantle is a very fine, slightly acidic film on the skin that acts as a barrier to bacteria and fungi. Cleansing products but also other insults to skin barrier such as aging, UV radiation can alter the skin barrier and the content of NMF. When NMF is lost, the acid mantle is disrupted and the skin barrier is weakened, which can lead to dry cracked skin and can compromise skin’s ability to protect against bacteria.
Therefore, there is a need for a personal cleansing product that effectively maintain or improve skin’s acid mantle and its ability to defend against bacteria.
SUMMARY OF THE INVENTION
A personal cleansing composition is provided and comprises:
(a) from about 1%to about 15%of an anionic surfactant by weight of the composition, wherein the anionic surfactant comprises sodium laureth (n) sulfate SLEnS, wherein n is the average moles of ethoxylation, wherein n equals to 1, 2 or 3, preferably sodium laureth (n) sulfate SLEnS, wherein n is the average moles of ethoxylation, wherein n equals to 1;
(b) from about 0.01%to about 1%of an organic acid having a pKa greater than about 2.7, preferably a pKa from about 2.75 to about 5, more preferably a pKa from about 3 to about 4.5, or a cosmetically acceptable salt thereof, or a mixture thereof, by weight of the composition; and wherein the pH of the personal cleansing composition is from about 5.0 to about 6.5.
The personal cleansing composition as set out hereinbefore is used for maintaining or improving the natural defensive ability of human skin against bacteria, preferably for maintaining or improving the natural defensive ability of human skin against Staphylococcus aureus.
The personal cleansing composition as set out hereinbefore is used for promoting the skin natural defense efficacy.
The personal cleansing composition as set out hereinbefore is used for maintaining or restoring the natural skin pH.
The personal cleansing composition as set out hereinbefore is used for balancing skin pH and retaining skin moisture.
A method for maintaining or improving the natural defensive ability of human skin against bacteria, preferably against Staphylococcus aureus, comprising the step of applying onto the human skin the personal cleansing composition as set out hereinbefore, following by rinsing off the composition.
A method for promoting the skin natural defense efficacy comprising the step of applying onto the human skin the personal cleansing composition as set out hereinbefore, following by rinsing off the composition.
A method for maintaining or restoring the natural skin pH comprising the step of applying onto the human skin the personal cleansing composition as set out hereinbefore, following by rinsing off the composition.
Definitions of terms
In this document, including in all embodiments of all aspects of the present invention, the following definitions apply unless specifically stated otherwise.
All percentages are by weight (w/w) of the composition, unless otherwise specified. “%wt.” means percentage by weight. References to ‘parts’ e.g. a mixture of 1 part X and 3 parts Y, is a ratio by weight. All ratios or percentages are weight ratios or weight percentages unless specifically stated otherwise.
An “active composition” is the composition absent water, and an “active ingredient” is the ingredient absent its water.
“QS” or “QSP” means sufficient quantity for 100%or for 100g. +/-indicates the standard deviation. All ranges are inclusive and combinable. The number of significant digits conveys neither a limitation on the indicated amounts nor on the accuracy of the measurements. All numerical amounts are understood to be modified by the word “about” .
All measurements are understood to be made at 25℃ and at ambient conditions, where “ambient conditions” means at 1 atmosphere (atm) of pressure and at 65%relative humidity, unless otherwise stated. “Relative humidity” refers to the ratio (stated as a percent) of the moisture content of air compared to the saturated moisture level at the same temperature and pressure. Relative humidity can be measured with a hygrometer, in particular with a probe hygrometer from
International.
Herein “min” means “minute” or “minutes” . Herein “mol” means mole. Herein “g” following a number means “gram” or “grams” . “Ex. ” means “example” . All amounts as they pertain to listed ingredients are based on the active level and do not include carriers or by-products that may be included in commercially available materials.
Herein, “comprising” means that other steps and other ingredients can be in addition. “Comprising” encompasses the terms “consisting of” and “consisting essentially of” . The compositions, methods, uses, and processes of the present invention can comprise, consist of, and consist essentially of the elements and limitations of the invention described herein, as well as any of the additional or optional ingredients, components, steps, or limitations described herein. Embodiments and aspects described herein may comprise or be combinable with elements, features or components of other embodiments and/or aspects despite not being expressly exemplified in combination, unless an incompatibility is stated.
As used herein, the articles including “a” and “an” when used in a claim, are understood to mean “one or more” of what is claimed or described.
The terms “include, ” “includes, ” and “including, ” as used herein are meant to be non-limiting.
Where amount ranges are given, these are to be understood as being the total amount of said ingredient in the composition, or where more than one species fall within the scope of the ingredient definition, the total amount of all ingredients fitting that definition, in the composition.
For example, if the composition comprises from 1%to 5%fatty alcohol, then a composition comprising 2%stearyl alcohol and 1%cetyl alcohol and no other fatty alcohol, would fall within this scope.
The amount of each particular ingredient or mixtures thereof described hereinafter can account for up to 100% (or 100%) of the total amount of the ingredient (s) in the composition.
The term “free of” as used herein means that the composition comprises 0%of an ingredient by weight of the composition, thus no detectable amount of the stated ingredient.
The term “substantially free of” as used herein means less than about 1%, less than about 0.8%, less than about 0.5%, less than about 0.3%, or less than an immaterial amount of by weight of the composition.
Herein “Comp. Ex. ” or “C. Ex. ” means comparative example; and “Ex. ” means example.
The term “molecular weight” or “M. Wt. ” as used herein refers to the weight average molecular weight unless otherwise stated. The weight average molecular weight can be measured by gel permeation chromatography ( “GPC” ) .
The term “personal cleansing composition” as used herein refers to compositions intended for topical application to the skin for cleansing.
The term “mixtures” as used herein is meant to include a simple combination of materials and any compounds that may result from their combination.
The term “room temperature” refers to a temperature of 25℃.
The term “rinse-off” as used herein means the intended product usage includes application to skin followed by rinsing and/or wiping the product from the skin within a few seconds to minutes of the application step. The product is generally applied and rinsed in the same usage event, for example, a shower or washing one’s hands.
The term “derivative” as used herein refers to structures which are not shown but which one skilled in the art would understand are variations of the basic compound.
The methods as disclosed herein are cosmetic methods or non-therapeutic methods.
The objects of the present invention are to provide personal cleansing products, methods and uses of the products, the structures and the respective compositions as described in the Summary or as described hereinbelow for fulfilling the technical effects or goals as set out herein. These objects and other advantages as may be apparent to those skilled in the art can be achieved through the present invention, which is described in the above Summary of the Invention and Detailed Description of the invention and which is defined in the claims which follow.
BENEFITS
Human skin is the body’s largest organ and is part of the body’s natural defense to microbial attack. The natural skin defense is made up of a multitude of components. For example, the skin’s natural defense includes the skin’s ability to be a physical barrier, the pH of the skin, the skin microbiome, lipids on the skin, chemical components of the skin, etc.
Human skin’s ability to provide a natural defense against microbial attack can be impacted by things with which it comes into contact during the day, like skin products. Bacteria does not only stay on the skin surface, but also go deep into skin. It compromises skin barrier, causing skin sensitivity and irritation.
It was found that a personal cleansing composition that can contain an anionic surfactant wherein the anionic surfactant comprises sodium laureth (n) sulfate SLEnS, wherein n is the average moles of ethoxylation, wherein n equals to 1, 2 or 3 and an organic acid having a pKa greater than about 2.7 can effectively help balance skin pH to maintain or improve skin’s acid mantle and its natural ability to defend against bacteria.
It was found that certain organic acid having a specific pKa can contribute to human skin’s protective layer to maintain the skin’s acid mantle, and maintain or improve its natural ability to defend against bacteria.
It is believed that an organic acid having a specific pKa greater than about 2.7, preferably a pKa from about 2.75 to about 5, more preferably a pKa from about 3 to about 4.5, as set out hereinafter can penetrate at least three layers into the skin, which can provide a deep layer of protection to users for at least about 12 hours, preferably for at least about 6 hours, more preferably for at least about 4 hours.
Testing of the skin’s natural defense can be performed according to the Method for Measuring Residual Antimicrobial Efficacy of a Product, described herein. Staphylococcus aureus is a logarithmic scale, measured in colony-forming unit (CFU) . DT is a logarithmic scale, which corresponds to level of bacteria.
The personal cleansing composition has a pH from about 5.0 to about 6.5, preferably from about 5.2 to about 6.0, more preferably from about 5.3 to about 5.8, even more preferably from about 5.4 to about 5.8, most preferably from about 5.5 to about 5.7. pH is measured according to the Product pH Measurement Test Method, described hereafter.
The personal cleansing composition may have a viscosity from about 2.75 Pa. s (about 2750 cps) to about 15 Pa. s (about 15,000 cps) , alternatively from about 3 Pa. s (about 3000 cps) to about 13 Pa. s (about 13,000 cps) , alternatively from about 4 Pa. s (about 4000 cps) to about 11 Pa.s (about 11,000 cps) , alternatively from about 5 Pa. s (about 5000 cps) to about 10 Pa. s (about 10,000 cps) , and alternatively from about 6 Pa. s (about 6000 cps) to about 10 Pa. s (about 9000 cps) , according to the Cone/Plate Viscosity Measurement, described herein.
ANIONIC SURFACTANT
The personal cleansing composition includes an anionic surfactant. Anionic surfactants can provide a cleaning benefit, lather properties, and rheology properties to the compositions.
The personal cleansing composition comprises from about 1%to about 15%, preferably from about 3%to about 13%, more preferably about from 5%to about 13%, even more preferably from about 8%to about 12%, or most preferably from about 9%to about 10%, by weight of the composition, of an anionic surfactant.
The anionic surfactant comprises sodium laureth (n) sulfate SLEnS, wherein n is the average moles of ethoxylation, wherein n equals to 1, 2 or 3.
Preferably, the anionic surfactant may comprise sodium laureth (n) sulfate SLEnS, wherein n is the average moles of ethoxylation, wherein n equals to 1.
The anionic surfactant may comprise a mixture of sodium laureth (3) sulfate SLE3S and sodium lauryl sulfate SLS.
Alternatively, the anionic surfactant may comprise a mixture of sodium laureth (1) sulfate and sodium lauryl sulfate.
In certain aspects, the personal cleansing composition may not comprise any sodium laureth (n) sulfate SLEnS, wherein n is the average moles of ethoxylation, wherein n is equals to 0, 2 or 3.
It is understood that a material such as SLEnS, for example, can comprise a significant amount of molecules which have no ethoxylate, 1 mole ethoxylate, 2 mole ethoxylate, 3 mole ethoxylate, and so on in a distribution which can be broad, narrow or truncated from n = 0 to 10. Hence, sodium laureth (1) sulfate (SLE1S) can comprise a significant amount of molecules which have no ethoxylate, 1 mole ethoxylate, 3 mole ethoxylate, and so on in a distribution which can be broad, narrow or truncated and still comprise sodium laureth (1) sulfate (SLE1S) where the average of the distribution is 1.
The personal cleansing composition may comprise from about 0.5%to about 10%of one or more additional anionic surfactants, preferably from about 0.75%to about 5%of one or more additional anionic surfactants, more preferably from about 1%to about 2%of one or more additional anionic surfactants by weight of the composition.
The one or more additional anionic surfactants may be selected from the group consisting of isethionate surfactants, sarcosinate surfactants, sulfosuccinate surfactants, sulfonate surfactants, sulfoacetate surfactants, glycinate surfactants, alaninate surfactants, glutamate surfactants, lactate surfactants, lactylate surfactants, glucose carboxylate surfactants, taurate surfactants, and mixtures thereof.
Suitable isethionate surfactants can include the reaction product of fatty acids esterified with isethionic acid and neutralized with sodium hydroxide. Suitable fatty acids for isethionate surfactants can be derived from coconut oil or palm kernel oil including amides of methyl tauride. Non-limiting examples of isethionates can be selected from the group consisting of sodium lauroyl methyl isethionate, sodium cocoyl isethionate, ammonium cocoyl isethionate, sodium hydrogenated cocoyl methyl isethionate, sodium lauroyl isethionate, sodium cocoyl methyl isethionate, sodium myristoyl isethionate, sodium oleoyl isethionate, sodium oleyl methyl isethionate, sodium palm kerneloyl isethionate, sodium stearoyl methyl isethionate, and mixtures thereof.
Non-limiting examples of sarcosinate surfactants can be selected from the group consisting of sodium lauroyl sarcosinate, sodium cocoyl sarcosinate, sodium myristoyl sarcosinate, TEA-cocoyl sarcosinate, ammonium cocoyl sarcosinate, ammonium lauroyl sarcosinate, dimer dilinoleyl bis-lauroylglutamate/lauroylsarcosinate, lauroyl sarcosinate, isopropyl lauroyl sarcosinate, potassium cocoyl sarcosinate, potassium lauroyl sarcosinate, sodium oleoyl sarcosinate, sodium palmitoyl sarcosinate, TEA-lauroyl sarcosinate, TEA-oleoyl sarcosinate, TEA-palm kernel sarcosinate, and mixtures thereof. Preferably, the sarcosinate surfactant may be selected from the group consisting of sodium lauroyl sarcosinate, sodium cocoyl sarcosinate, and mixtures thereof.
Non-limiting examples of sulfosuccinate surfactants can include disodium N-octadecyl sulfosuccinate, disodium lauryl sulfosuccinate, diammonium lauryl sulfosuccinate, sodium lauryl sulfosuccinate, disodium laureth sulfosuccinate, tetrasodium N- (1, 2-dicarboxyethyl) -N-octadecyl sulfosuccinnate, diamyl ester of sodium sulfosuccinic acid, dihexyl ester of sodium sulfosuccinic acid, dioctyl esters of sodium sulfosuccinic acid, and mixtures thereof.
Non-limiting examples of sulfonate surfactants can include alpha olefin sulfonates, linear alkylbenzene sulfonates, sodium laurylglucosides hydroxypropylsulfonate, and mixtures thereof.
Non-limiting examples of sulfoacetate surfactants can include sodium lauryl sulfoacetate, ammonium lauryl sulfoacetate, and mixture thereof.
Non-limiting examples of glycinate surfactants can include sodium cocoyl glycinate, sodium lauroyl glycinate, and mixture thereof.
Non-limiting example of alaninate surfactants can include sodium cocoyl alaninate, sodium lauroyl alaninate, sodium N-dodecanoyl-l-alaninate, and mixtures thereof. Preferably, the alaninate surfactant may include sodium cocoyl alaninate.
Non-limiting examples of glutamate surfactants can be selected from the group consisting of sodium cocoyl glutamate, disodium cocoyl glutamate, ammonium cocoyl glutamate, diammonium cocoyl glutamate, sodium lauroyl glutamate, disodium lauroyl glutamate, sodium cocoyl hydrolyzed wheat protein glutamate, disodium cocoyl hydrolyzed wheat protein glutamate, potassium cocoyl glutamate, dipotassium cocoyl glutamate, potassium lauroyl glutamate, dipotassium lauroyl glutamate, potassium cocoyl hydrolyzed wheat protein glutamate, dipotassium cocoyl hydrolyzed wheat protein glutamate, sodium capryloyl glutamate, disodium capryloyl glutamate, potassium capryloyl glutamate, dipotassium capryloyl glutamate, sodium undecylenoyl glutamate, disodium undecylenoyl glutamate, potassium undecylenoyl glutamate, dipotassium undecylenoyl glutamate, disodium hydrogenated tallow glutamate, sodium stearoyl glutamate, disodium stearoyl glutamate, potassium stearoyl glutamate, dipotassium stearoyl glutamate, sodium myristoyl glutamate, disodium myristoyl glutamate, potassium myristoyl glutamate, dipotassium myristoyl glutamate, sodium cocoyl/hydrogenated tallow glutamate, sodium cocoyl/palmoyl/sunfloweroyl glutamate, sodium hydrogenated tallowoyl glutamate, sodium olivoyl glutamate, disodium olivoyl glutamate, sodium palmoyl glutamate, disodium palmoyl glutamate, TEA-cocoyl glutamate, TEA-hydrogenated tallowoyl glutamate, TEA-lauroyl glutamate, and mixtures thereof.
Non-limiting example of lactate surfactants can include sodium lactate.
Non-limiting examples of lactylate surfactants can include sodium lauroyl lactylate, sodium cocoyl lactylate, and mixture thereof.
Non-limiting examples of glucose carboxylate surfactants can include sodium lauryl glucoside carboxylate, sodium cocoyl glucoside carboxylate, and mixtures thereof.
Non-limiting examples of taurate surfactants can include sodium methyl cocoyl taurate, sodium methyl lauroyl taurate, sodium methyl oleoyl taurate, and mixtures thereof.
Preferably, the additional anionic surfactant may be selected from the group consisting of sodium cocoyl alaninate, sodium lauroyl sarcosinate, sodium cocoyl sarcosinate, and mixtures thereof.
In that case, the personal cleansing composition may include from about 1%to about 2%of one or more additional anionic surfactants by weight of the composition.
The addition of an additional surfactant as set out above can help to enhance further the natural antimicrobial defensive ability of human skin.
CO-SURFACTANT
The personal cleansing composition comprises from about 1%to about 15%of one or more cosurfactants, preferably from about 1.5%to about 5%of one or more cosurfactants, more preferably from about 1.5%to about 2%of one or more cosurfactants by weight of the composition. The one or more cosurfactants may be selected from the group consisting of amphoteric surfactants, zwitterionic surfactants, and mixtures thereof.
The personal cleansing composition may include at least one of an amphoteric surfactant and a zwitterionic surfactant. Suitable amphoteric or zwitterionic surfactants can include those described in U.S. Patent No. 5,104,646 and U.S. Patent No. 5,106,609.
Amphoteric surfactants can include those that can be broadly described as derivatives of aliphatic secondary and tertiary amines in which an aliphatic radical can be straight or branched chain and wherein an aliphatic substituent can contain from 8 to 18 carbon atoms such that one carbon atom can contain an anionic water solubilizing group, e.g., carboxy, sulfonate, sulfate, phosphate, or phosphonate. Examples of compounds falling within this definition can be sodium 3-dodecyl-aminopropionate, sodium 3-dodecylaminopropane sulfonate, sodium lauryl sarcosinate, N-alkyltaurines such as the one prepared by reacting dodecylamine with sodium isethionate according to the teaching of U.S. Patent No. 2,658,072, N-higher alkyl aspartic acids such as those produced according to the teaching of U.S. Patent No. 2,438,091, and products described in U.S. Patent No. 2,528,378.
Alternatively or in addition, the one or more cosurfactants included in the personal cleansing composition described herein may comprise an amphoteric surfactant that is selected from the group consisting of sodium lauroamphoacetate, sodium cocoamphoacetate, disodium lauroamphoacetate, disodium cocodiamphoacetate, and mixtures thereof.
Zwitterionic surfactants suitable for use in the one or more cosurfactants of the personal cleansing composition described herein may include those that are broadly described as derivatives of aliphatic quaternary ammonium, phosphonium, and sulfonium compounds, in which the aliphatic radicals can be straight or branched chains, and wherein one of the aliphatic substituents can contain from 8 to 18 carbon atoms and one can contain an anionic group, e.g., carboxy, sulfonate, sulfate, phosphate, or phosphonate. The zwitterionic surfactant included in the personal cleansing composition described herein may include one or more betaines, including cocoamidopropyl betaine.
Alternatively, the amphoteric or zwitterionic surfactant may be selected from cocamidopropyl betaine, lauramidopropyl betaine, coco-betaine, lauryl betaine, cocoamphoacetate, cocoamphodiacetate, lauroamphoacetate, lauroamphodiacetate, lauramine oxide, and mixtures thereof.
Examples of betaine zwitterionic surfactants may include coco dimethyl carboxymethyl betaine, cocoamidopropyl betaine (CAPB) , coco-betaine, lauryl amidopropyl betaine (LAPB) , oleyl betaine, lauryl dimethyl carboxymethyl betaine, lauryl dimethyl alpha-carboxyethyl betaine, cetyl dimethyl carboxymethyl betaine, lauryl bis- (2-hydroxyethyl) carboxymethyl betaine, stearyl bis- (2-hydroxypropyl) carboxymethyl betaine, oleyl dimethyl gamma-carboxypropyl betaine, lauryl bis- (2-hydroxypropyl) alpha-carboxyethyl betaine, and mixtures thereof. Examples of sulfobetaines may include coco dimethyl sulfopropyl betaine, stearyl dimethyl sulfopropyl betaine, lauryl dimethyl sulfoethyl betaine, lauryl bis- (2-hydroxyethyl) sulfopropyl betaine and mixtures thereof.
The one or more cosurfactants may comprise a zwitterionic surfactant, preferably a betaine and/or a sultaine, more preferably a zwitterionic surfactant selected from the group consisting of cocamidopropyl betaine, lauramidopropyl betaine, cocamidopropyl hydroxysultaine and mixtures thereof, even more preferably cocamidopropyl hydroxysultaine or cocamidopropyl betaine.
Nonionic surfactants suitable for use can include those selected from the group consisting of alkyl ethoxylates, alkyl glucosides, polyglucosides (e.g., alkyl polyglucosides, decyl polyglucosides) , polyhydroxy fatty acid amides, alkoxylated fatty acid esters, sucrose esters, amine oxides, or mixtures thereof. Some exemplary nonionic surfactants can include cocamide monoethanolamine, decyl glucoside, or a combination thereof.
Additional surfactants and other ingredients suitable for personal cleansing compositions are found in US Pub. No. 2020/0046623, which is hereby incorporated by reference.
ORGANIC ACID
The personal cleansing composition comprises from about 0.01%to about 1%, preferably from about 0.02%to about 0.8%, more preferably from about 0.03%to about 0.5%, even more preferably from about 0.05%to about 0.3%, most preferably from about 0.05%to about 0.15%of an organic acid having a pKa greater than about 2.7 or a cosmetically acceptable salt thereof, or a mixture thereof, by weight of the composition.
The personal cleansing composition comprises an organic acid having a pKa greater than about 2.7, preferably a pKa from about 2.75 to about 5.0, more preferably a pKa from about 3.0 to about 4.5, or a cosmetically acceptable salt thereof, or a mixture thereof.
The cosmetically acceptable salt of the organic acid having a pKa as set out above may be sodium, potassium, calcium, magnesium, or ammonium salts.
Alternatively, the personal cleansing composition comprises an organic acid having a pKa greater than about 2.7, preferably a pKa from about 2.75 to about 5.0, more preferably a pKa from about 3.0 to about 4.5, or a mixture thereof. The personal cleansing composition does not comprise any cosmetically acceptable salt of the organic acid.
The organic acid having a pKa greater than about 2.7 may be selected from the group consisting of 2-pyrrolidone-5-carboxylic acid (pidolic acid) , adipic acid, gluconolactone acid, glutamic acid, glycolic acid, glutaric acid, tartaric acid, ascorbic acid, benzoic acid, salicylic acid, malic acid, succinic acid, lactic acid, a cosmetically acceptable salt thereof, and mixtures thereof.
The organic acid having a pKa from about 2.75 to about 5.0 may be preferably selected from the group consisting of 2-pyrrolidone-5-carboxylic acid (pidolic acid) , adipic acid, glutamic acid, glycolic acid, glutaric acid, tartaric acid, ascorbic acid, benzoic acid, malic acid, succinic acid, lactic acid, a cosmetically acceptable salt thereof, and mixtures thereof.
The organic acid having a pKa from about 3.0 to about 4.5 may be more preferably selected from the group consisting of 2-pyrrolidone-5-carboxylic acid, adipic acid, gluconic acid, glycolic acid, glutaric acid, ascorbic acid, benzoic acid, malic acid, succinic acid, lactic acid, a cosmetically acceptable salt thereof, and mixtures thereof.
The organic acid having a pKa from about 3.0 to about 4.5 may be even more preferably selected from the group consisting of 2-pyrrolidone-5-carboxylic acid, adipic acid, gluconic acid, glycolic acid, glutaric acid, malic acid, succinic acid, lactic acid, a cosmetically acceptable salt thereof, and mixtures thereof.
Most preferably, the organic acid may comprise 2-pyrrolidone-5-carboxylic acid, or a cosmetically acceptable salt thereof, or a mixture thereof.
The cosmetically acceptable salt of 2-pyrrolidone-5-carboxylic acid may be sodium, potassium, calcium, magnesium, or ammonium salts.
The personal cleansing composition may comprise from about 0.02%to about 0.8%, preferably from about 0.03%to about 0.5%, more preferably from about 0.05%to about 0.3%, most preferably from about 0.05%to about 0.15%of 2-pyrrolidone-5-carboxylic acid by weight of the composition.
Without wishing to be bound by theory, the organic acid as set out above can protonate the carboxylate functionalities on the phospholipid membrane of bacteria and reduce the tendency of the membrane to electronically repel anionic surfactants, thereby facilitating proper interaction between the present, anionic surfactants and the membrane.
Moreover, the organic acids as set out hereinbefore can help facilitating the creation of a low pH buffer on the surface of a substrate, thereby promoting human skin maintain its natural barrier against bacteria.
Also, the organic acids as set out hereinbefore, preferably 2-pyrrolidone-5-carboxylic acid, provided in a personal cleansing composition comprising the anionic surfactant and the pH as set out herein can be deposited onto skin and through skin layers.
pH
The pH of the personal cleansing composition is from about 5.0 to about 6.5, preferably from about 5.2 to about 6.0, more preferably from about 5.3 to about 5.8, even more preferably from about 5.4 to about 5.8, most preferably 5.5 to 5.7.
The pH of the skin is typically naturally acidic, namely between about 4.5 and about 6.5. An acidic skin pH can help to activating specific enzyme to regulate skin activity and to balance the acid mantle of the skin. Such balanced acid mantle of the skin together with the antimicrobial peptites (AMPs) present in the skin layers can help the skin for maintaining or improving its natural barrier against bacteria, especially against Staphylococcus aureus.
Hence, the personal cleansing composition comprises an acidic pH as defined above to help the skin to reinforce its natural barrier against bacteria.
It has also been found that a pH from about 5.0 to about 6.5 could also help to improve the stability of the personal cleansing composition. As an example, the stability of the personal cleansing composition may be altered when comprising optional ingredients such as fragrances. Perfume instability can typically be observed when specific fragrances might be hydrolyzed in an acidic medium. A relatively higher pH from about 5.0 to about 6.5 can help to prevent any perfume or any pH-sensitive ingredient instability.
A variety of compounds may be used to adjust the pH value of a composition. Such suitable compounds can include, but are not limited to, acetic acid, hydrochloric acid, sodium hydroxide, magnesium hydroxide, triethylamine, diethylamine, ethylamine, monoethanol amine, and any mixtures thereof. The personal cleansing composition may comprise greater than about 0%to about 2%of the pH adjusting agent by weight of the composition, preferably wherein the pH adjusting agent comprises citric acid.
SOLUBILIZER
The personal cleansing composition may include one or more solubilizers such as sugar alcohols or glycols. The sugar alcohols can include sorbitol. The glycols can include propylene glycol, dipropylene glycol, polyethylene glycol, derivatives thereof, and mixtures thereof. In one example, the personal cleansing compositions can minimize the amount of solubilizers.
The personal cleansing composition may include no more than about 10%, alternatively no more than about 5%, alternatively no more than about 3%, alternatively no more than about 1%, preferably greater than about 0%but less than about 3%, more preferably greater than about 0%but less than about 1%, by weight of the composition, of one or more solubilizers. The personal cleansing composition may be substantially free of solubilizers, alternatively the composition may be free of solubilizers.
STRUCTURANT
The personal cleansing composition may include one or more hydrophilic structurants such as carbohydrate structurants and gums. Some suitable carbohydrate structurants include raw starch (corn, rice, potato, wheat, and the like) and pregelatinized starch. Some suitable gums include carrageenan, guar gum and xanthan gum. The personal cleansing composition may include from about 0.1%to about 30%, from about 2%to about 25%, or from about 4%to about 20%, by weight of the composition, of one or more carbohydrate structurants.
HUMECTANT
The personal cleansing composition may include one or more humectants. Examples of humectants can include polyhydric alcohols. Further, humectants such as glycerin can be included the personal cleansing composition as a result of production or as an additional ingredient. For example, glycerin can be a by-product after saponification of the cleansing composition. Including additional humectant can result in a number of benefits such as improvement in hardness of the personal cleansing composition, decreased water activity of the personal cleansing composition, and reduction of a weight loss rate of the cleansing composition over time due to water evaporation. The personal cleansing composition may comprise from greater than about 0%to about 10%of one or more humectants, by weight of the composition.
INORGANIC SALT
The personal cleansing composition may include one or more inorganic salts. Inorganic salts can help to maintain a particular water content or level of the composition and improve hardness of the composition. The inorganic salts can also help to bind the water in the composition to prevent water loss by evaporation or other means. The personal cleansing composition may optionally include from about 0.01%to about 15%, preferably from about 1%to about 12%, more preferably from about 2.5%to about 10.5%, by weight of the composition, of one or more inorganic salts. Examples of suitable inorganic salts can include magnesium nitrate, trimagnesium phosphate, calcium chloride, sodium carbonate, sodium aluminum sulfate, disodium phosphate, sodium polymetaphosphate, sodium magnesium succinate, sodium tripolyphosphate, aluminum sulfate, aluminum chloride, aluminum chlorohydrate, aluminum-zirconium trichlorohydrate, aluminum-zirconium trichlorohydrate glycine complex, zinc sulfate, ammonium chloride, ammonium phosphate, calcium acetate, calcium nitrate, calcium phosphate, calcium sulfate, ferric sulfate, magnesium chloride, magnesium sulfate, and tetrasodium pyrophosphate.
SKIN BENEFIT AGENT
The personal cleansing composition may include from about 0.5%to about 20%of one or more skin benefit agents or actives, by weight of the composition.
Examples of suitable skin benefit agents can include petrolatum, glyceryl monooleate, mineral oil, natural oils, and mixtures thereof. Additional examples of skin benefit agents can include water insoluble or hydrophobic benefit agents.
Non-limiting examples of glycerides suitable for use as hydrophobic skin benefit agents herein can include castor oil, safflower oil, corn oil, walnut oil, peanut oil, olive oil, cod liver oil, almond oil, avocado oil, palm oil, sesame oil, vegetable oils, sunflower seed oil, soybean oil, vegetable oil derivatives, coconut oil and derivatized coconut oil, cottonseed oil and derivatized cottonseed oil, jojoba oil, cocoa butter, and mixtures thereof.
Non-limiting examples of alkyl esters suitable for use as hydrophobic skin benefit agents herein can include isopropyl esters of fatty acids and long chain esters of long chain (e.g., C10-C24) fatty acids, e.g., cetyl ricinoleate, non-limiting examples of which can include isopropyl palmitate, isopropyl myristate, cetyl riconoleate, and stearyl riconoleate. Other example can include hexyl laurate, isohexyl laurate, myristyl myristate, isohexyl palmitate, decyl oleate, isodecyl oleate, hexadecyl stearate, decyl stearate, isopropyl isostearate, diisopropyl adipate, diisohexyl adipate, dihexyldecyl adipate, diisopropyl sebacate, acyl isononanoate lauryl lactate, myristyl lactate, cetyl lactate, and mixtures thereof.
Non-limiting examples of polyglycerin fatty acid esters suitable for use as hydrophobic skin benefit agents herein can include decaglyceryl distearate, decaglyceryl diisostearate, decaglyceryl monomyriate, decaglyceryl monolaurate, hexaglyceryl monooleate, and mixtures thereof.
PRESERVATIVE
The personal cleansing composition may include one or more preservatives, generally included at less than about 2%by weight of the composition, preferably from 0.1%to 0.5%by weight of the composition. Such suitable preservatives can include, but are not limited to, benzyl alcohol, kathon, propylene glycol, hydroxy acetophenone, sodium benzoate, disodium ethylenediaminetetraacetic acid (EDTA) , parabene, phenoxy ethanol, imidazolidinyl urea, and any mixture thereof. The one or more preservatives may preferably comprise sodium benzoate, or a mixture of sodium benzoate and kathon. Kathon is composed of methylchloroisothiazolinone and methylisothiazolinone.
OPTIONAL INGREDIENTS
As can be appreciated, the compositions described herein may include a variety of optional components to tailor the properties and characteristics of the composition. As can be appreciated, suitable optional components are well known and can generally include any components which are physically and chemically compatible with the essential components of the compositions described herein. Optional components should not otherwise unduly impair product stability, aesthetics, or performance. Individual concentrations of optional components can generally range from about 0.001%to about 10%, by weight of the composition. Optional components can be further limited to components which will not impair the clarity of a translucent composition.
Optional components may include, but are not limited to, conditioning agents (including hydrocarbon oils, fatty esters, silicones) , cationic polymers, anti-dandruff actives, and chelating agents. Additional suitable optional ingredients include but are not limited to encapsulated and non-encapsulated perfumes or fragrances, colorants, particles, anti-microbials, foam boosters, anti-static agents, moisturizing agents, propellants, self-foaming agents, pH adjusting agents and buffers, preservatives, pearlescent agents, opacifiers, sensates, suspending agents, solvents, diluents, anti-oxidants, vitamins, and mixtures thereof.
The personal cleansing composition may comprise from 0.1%to 1.0%, preferably from 0.5%to 0.6%of a fragrance, by weight of the composition.
Such optional ingredients should be physically and chemically compatible with the components of the composition, and should not otherwise unduly impair product stability, aesthetics, or performance. The CTFA Cosmetic Ingredient Handbook, Tenth Edition (published by the Cosmetic, Toiletry, and Fragrance Association, Inc., Washington, D. C. ) (2004) (hereinafter "CTFA" ) , describes a wide variety of nonlimiting materials that can be added to the composition herein.
ANTIMICROBIAL ACTIVE
The personal cleansing composition may be substantially free of an antimicrobial active. Preferably, the personal cleansing composition may comprise less than about 1%of an antimicrobial active, by weight of the composition. More preferably, the personal cleansing composition may free of an antimicrobial active. Most preferably, the personal cleansing composition may comprise less than about 0.1%of an antimicrobial active.
However, in some aspects, the personal cleansing composition may comprise an antimicrobial active. Preferably, the antimicrobial active may be piroctone olamine.
A personal cleansing composition may be provided and may comprise:
(a) from about 1%to about 15%of an anionic surfactant by weight of the composition, wherein the anionic surfactant comprises sodium laureth (n) sulfate SLEnS, wherein n is the average moles of ethoxylation, wherein n equals to 1, 2 or 3, preferably sodium laureth (n) sulfate SLEnS, wherein n is the average moles of ethoxylation, wherein n equals to 1;
(b) from about 0.01%to about 1%of an organic acid having a pKa greater than about 2.7, preferably a pKa from about 2.75 to about 5, more preferably a pKa from about 3 to about 4.5, or a cosmetically acceptable salt thereof, or a mixture thereof, by weight of the composition;
(c) an antimicrobial active, preferably wherein the antimicrobial active is piroctone olamine; and
wherein the pH of the personal cleansing composition is from 3.5 to 6.5, preferably from about 5.0 to about 6.5.
The personal cleansing composition may comprise from about 0.01%to about 2%, preferably from about 0.1%to about 0.75%, more preferably from about 0.2%to about 0.5%of piroctone olamine, by weight of the composition.
The personal cleansing composition as set out just above may be used for helping human skin maintain or improve its natural barrier against bacteria.
All the limitations and aspects as disclosed hereinabove might apply. In some aspects, the personal cleansing composition may include from about 1%to about 10%of one or more additional anionic surfactants, preferably from about 3%to about 9%of one or more additional anionic surfactants, more preferably from about 5%to about 9%of one or more additional anionic surfactants by weight of the composition.
The one or more additional anionic surfactants may be selected from the group consisting of isethionate surfactants, sarcosinate surfactants, glycinate surfactants, alaninate surfactants, glutamate surfactants, taurate surfactants, and mixtures thereof. Preferably, the one or more additional anionic surfactants may be selected from the group consisting of sarcosinate surfactants, alaninate surfactants, glutamate surfactants, taurate surfactants, and mixtures thereof.
Non-limiting examples of sarcosinate surfactants can be selected from the group consisting of sodium lauroyl sarcosinate, sodium cocoyl sarcosinate, sodium myristoyl sarcosinate, TEA-cocoyl sarcosinate, ammonium cocoyl sarcosinate, ammonium lauroyl sarcosinate, dimer dilinoleyl bis-lauroylglutamate/lauroylsarcosinate, lauroyl sarcosinate, isopropyl lauroyl sarcosinate, potassium cocoyl sarcosinate, potassium lauroyl sarcosinate, sodium oleoyl sarcosinate, sodium palmitoyl sarcosinate, TEA-oleoyl sarcosinate, TEA-palm kernel sarcosinate, and mixtures thereof. Preferably, the sarcosinate surfactant may be selected from the group consisting of sodium lauroyl sarcosinate, sodium cocoyl sarcosinate, and mixtures thereof.
Non-limiting example of alaninate surfactants can include sodium cocoyl alaninate, sodium lauroyl alaninate, sodium N-dodecanoyl-l-alaninate, and mixtures thereof. Preferably, the alaninate surfactant may include sodium cocoyl alaninate.
Non-limiting examples of glutamate surfactants can be selected from the group consisting of sodium cocoyl glutamate, disodium cocoyl glutamate, ammonium cocoyl glutamate, diammonium cocoyl glutamate, sodium lauroyl glutamate, disodium lauroyl glutamate, sodium cocoyl hydrolyzed wheat protein glutamate, disodium cocoyl hydrolyzed wheat protein glutamate, potassium cocoyl glutamate, dipotassium cocoyl glutamate, potassium lauroyl glutamate, dipotassium lauroyl glutamate, potassium cocoyl hydrolyzed wheat protein glutamate, dipotassium cocoyl hydrolyzed wheat protein glutamate, sodium capryloyl glutamate, disodium capryloyl glutamate, potassium capryloyl glutamate, dipotassium capryloyl glutamate, sodium undecylenoyl glutamate, disodium undecylenoyl glutamate, potassium undecylenoyl glutamate, dipotassium undecylenoyl glutamate, disodium hydrogenated tallow glutamate, sodium stearoyl glutamate, disodium stearoyl glutamate, potassium stearoyl glutamate, dipotassium stearoyl glutamate, sodium myristoyl glutamate, disodium myristoyl glutamate, potassium myristoyl glutamate, dipotassium myristoyl glutamate, sodium cocoyl/hydrogenated tallow glutamate, sodium cocoyl/palmoyl/sunfloweroyl glutamate, sodium hydrogenated tallowoyl glutamate, sodium olivoyl glutamate, disodium olivoyl glutamate, sodium palmoyl glutamate, disodium palmoyl glutamate, TEA-cocoyl glutamate, TEA-hydrogenated tallowoyl glutamate, TEA-lauroyl glutamate, and mixtures thereof.
Non-limiting examples of taurate surfactants can include sodium methyl cocoyl taurate, sodium methyl lauroyl taurate, sodium methyl oleoyl taurate, and mixtures thereof.
METHOD
A non-therapeutic method for maintaining or improving the natural antimicrobial defense ability of human skin against bacteria, especially against Staphylococcus aureus, is provided and comprises the step of applying onto the human skin the personal cleansing composition as set out hereinbefore, following by rinsing off the composition.
Alternatively, a non-therapeutic method for promoting the skin natural defense efficacy against bacteria is provided and comprises the step of applying onto the human skin the personal cleansing composition as set out hereinbefore, following by rinsing off the composition.
A method for maintaining or restoring the natural skin pH is also provided and comprises the step of applying onto the human skin the personal cleansing composition as set out hereinbefore, following by rinsing off the composition.
Skin surface pH contributes to the skin natural antimicrobial barrier. If the acid mantel of the skin is damaged/impaired, natural skin protection function will be impacted. A treatment with a personal cleansing composition as set out hereinbefore that can help for protecting, maintaining or even further restoring the natural skin pH.
FORMS AND USES
Product Form
The personal cleansing composition may be presented in typical personal cleansing formulations. They may be in the form of solutions, dispersion, emulsions, foams, and other delivery mechanisms. The personal cleansing composition may be a rinse-off composition.
The personal cleansing composition may be extrudable or dispensable from a single chamber package. The personal cleansing compositions can be in the form of liquid, semi-liquid, cream, lotion or gel, or solid compositions intended for topical application to skin.
Examples of personal cleansing compositions can include but are not limited to body wash, moisturizing body wash, foaming body wash, shower gels, a shower or bath cream, skin cleansers, cleansing milks, body wash, in shower body moisturizer, gel, emulsion, oil, mousse or spray.
The personal cleansing composition may be not in the form of a liquid hand wash or a liquid hand sanitizer.
The product forms contemplated for purposes of defining the personal cleansing compositions and methods are rinse-off formulations by which it is meant that the product is applied topically to the skin and then subsequently (i.e., within minutes) rinsed away with water, or otherwise wiped off using a substrate or other suitable removal means.
Uses
The personal cleansing composition as set out hereinabove may be used for maintaining or improving the natural antimicrobial defense ability of human skin, preferably against Staphylococcus aureus.
The personal cleansing composition as set out hereinabove may be used for promoting the skin natural defense efficacy.
The personal cleansing composition as set out hereinabove may be used for maintaining or restoring the natural skin pH.
The personal cleansing composition as set out hereinbefore may be used for balancing skin pH and retaining skin moisture.
The personal cleansing composition as set out hereinabove may be used for depositing an organic acid as defined hereinabove onto skin or through the skin layers, preferably wherein the organic acid is 2-pyrrolidone-5-carboxylic acid.
All the limitations and aspects as disclosed hereinabove for the personal cleansing composition might apply herein below.
A personal cleansing composition is provided and comprises:
(a) from 1%to 15%of an anionic surfactant by weight of the composition, wherein the anionic surfactant comprises sodium laureth (n) sulfate SLEnS, wherein n is the average moles of ethoxylation, wherein n equals to 1, 2 or 3;
(b) from 0.01%to 1%of an organic acid having a pKa greater than 2.7, preferably a pKa from 2.75 to 5, more preferably a pKa from 3 to 4.5, or a cosmetically acceptable salt thereof, or a mixture thereof, by weight of the composition; and
wherein the pH of the personal cleansing composition is from 5.0 to 6.5; for use in a method of maintaining or improving the natural antimicrobial defense ability of human skin against bacteria, preferably against Staphylococcus aureus.
Such personal cleansing composition can help for delivering long-lasting-deep layer skin protection, namely up to 12 hours, preferably for 3 skin layers, against opportunistic pathogenic microorganisms, preferably against Staphylococcus aureus.
A personal cleansing composition is also provided and comprises:
(a) from 1%to 15%of an anionic surfactant by weight of the composition, wherein the anionic surfactant comprises sodium laureth (n) sulfate SLEnS, wherein n is the average moles of ethoxylation, wherein n equals to 1, 2 or 3;
(b) from 0.01%to 1%of an organic acid having a pKa greater than 2.7, preferably a pKa from 2.75 to 5, more preferably a pKa from 3 to 4.5, or a cosmetically acceptable salt thereof, or a mixture thereof, by weight of the composition; and
wherein the pH of the personal cleansing composition is from 5.0 to 6.5; in a method of maintaining or improving the natural antimicrobial defense ability of human skin against bacteria, preferably against Staphylococcus aureus; characterized in that the personal cleansing composition is applied onto the human skin following by rinsing off the composition.
TEST METHODS
It is understood that the Test Methods that are disclosed in the Test Methods Section of the present application should be used to determine the respective values of the parameters of Applicants’ invention as such invention is described and claimed herein.
Cone/Plate Viscosity Measurement
The viscosity of the personal cleansing composition is measured by a Cone/Plate Controlled Stress Brookfield Rheometer R/SPlus, by Brookfield Engineering Laboratories, Stoughton, MA. The cone used (Spindle C-75-1) has a diameter of 75 mm and 1° angle. The viscosity is determined using a steady state flow experiment at constant shear rate of 2 s
-1 and at temperature of 26.5 ℃. The sample size is 2.5 mL and the total measurement reading time is 3 minutes.
Measuring Residual Antimicrobial Efficacy of a Product
The protocol provides a non-invasive method for evaluating the residual antimicrobe efficacy of a personal cleansing against designated bacteria. The method includes in vivo product application, skin stratum corneum sampling via tape stripping, germ challenge test on skin samples on the tape strip, and germ load quantification via
Detection time (DT) .
The test organism is Staphylococcus aureus (
6538/
27127) . Ideally, the strain is within 5 generations and has a routine identification at a frequency as makes sense for the bacteria and the test.
The test organism is prepared for the study. For S. aureus, refresh the test organism by streaking on a trypticase soy agar (TSA) plate and growing 18-24 hrs. On the second day, inoculate 1 colony of organism in a 50 mL tube containing 30 mL trypticase soy broth (TSB) , and grow at 35±2℃ for 18 hours ±15min. On the test day, dilute the above bacteria culture by 1:10 or other concentrations to new TSB (e.g. 0.5 mL culture to 4.5 mL TSB media) . The test organism culture is used within half an hour for inoculating tape strips for all samples tested.
A) Product Treatment and Sampling Protocol
A target demographic is selected for testing, for example healthy individuals ages 20-60 inclusive. Six to seven different subjects are tested. The subjects can be instructed to have a wash out period. For example, the wash out period can be to wash with a prescribed soap for 5 days, shower on day 6 with City Water only, and to refrain from taking a shower on day 7.
After the wash out period, a baseline skin sample may be taken on the target site prior to any product application. This is recorded as timepoint baseline. Then, the subjects are either instructed on how to do the following steps or a trained professional may do the steps on the subject. Utilizing tap water with a temperature of 35℃ +/-2℃ and a water flow rate of 4.0 L/min +/-0.3 L/min wet the volar surface of the forearm under the running water. For the liquid products tested herein, 0.7 mL of product was dispensed on the test subject’s forearm and spread evenly for 15 seconds. If necessary, continue to rub the lather on the forearm using the same up-and-down motion from the wrist to the elbow, for an additional 45 seconds. Rinse the forearm for 15 seconds by holding the arm under the running water. Do not rub the arm during rinsing. Remove the arm from the running water. Pat the arm dry with a paper towel without rubbing. The site is now ready for skin sampling with an adhesive. This is recorded as timepoint zero hour. The above steps are repeated three times on the same day before sampling.
Once the target site, here the arm, is ready for sampling, after the third wash, a strip of adhesive tape is adhered to the forearm avoiding folds. The skin site of interest can be marked in advance for consistency. To keep uniform pressure and reach optimal adhesive bond, a roller can be used to press the tape onto the skin surface (ex. twice on each site) . Then, the tapes were peeled off from the skin and placed on the surface of a TSA agar plate with the skin sample side up.The tape strips can also be inoculated prior to being placed on the TSA agar plate.
B) Prepping and Testing with an optical detection method (ex.
) Inoculate 10 μL of the tested microorganism culture on the skin sample side of each tape strip. Spread evenly over the tape surface, for example, with a sterile inoculation loop or pipette tip. Use one inoculation loop or pipette tip for each tape strip, and discard inoculation loop or pipette tip after use. Allow the inoculum to visually dry on the surface of the tape strip (approximately ~3-5 minutes) .
The inoculated test strips can then be prepped for sampling measurement depending on what is intended to be measured. For example, if the inoculated test strips are going to be run through an optical analysis for detection of microbial growth, then the inoculated tape strip residing on the TSA agar plate is placed into a humidified incubator at 35℃ and 60%± 20%relative humidity until time of collection (e.g. baseline=immediately before washing, t=0 is immediately after washing, t=3 is three hours after washing) .
At each sampling time, aseptically transfer each tape into one NF-TVC (non-fermenting total viable count) vial for continuous monitoring for 24 hours to determine the detection times (DTs) . Soleris parameters can be set as: Temperature 34℃; Threshold: 10; Shuteye: 25; Skip 1. The detection time can be converted to the logCFU count by generating a standard calibration curve of DT vs. LogCFU.
C) Data analysis:
The detection time was measured for each subject at each timepoint (baseline and zero hour) . In the first step, delta detection time was calculated by subtraction of the baseline by zero hour. In the second step, mean delta detection time value was calculated based on the testing leg. Finally, the delta [delta detection time] value was calculated by the difference between the two testing legs.
Multiple layer test with 12 hours detection time:
The same protocol for providing a non-invasive method for evaluating the residual antimicrobe efficacy of a personal cleansing composition against designated bacteria was used. The same wash out as set out above was carried out.
After the wash out period, a baseline skin sample may be taken on the target site prior to any product application. This is recorded as timepoint baseline. Then, the subjects are either instructed on how to do the following steps or a trained professional may do the steps on the subject. Utilizing tap water with a temperature of 35℃ +/-2℃ and a water flow rate of 4.0 L/min +/-0.3 L/min wet the volar surface of the forearm under the running water. For the liquid products tested herein, 0.7 mL of product was dispensed on the test subject’s forearm and spread evenly for 15 seconds. Then, continue to rub the lather on the forearm using the same up-and-down motion from the wrist to the elbow, for an additional 45 seconds. Rinse the forearm for 15 seconds by holding the arm under the running water. Do not rub the arm during rinsing. Remove the arm from the running water. Pat the arm dry with a paper towel without rubbing. Then, repeat this step for another two times. Totally, there are three washes. After that, the skin site is ready for sampling. This sampling timepoint is recorded as timepoint zero hour. After that, wait for 12 hours without any treatment. And then do the skin sampling (adhesive tape) and this is recorded as 12 hours timepoint.
In this study, three layers timepoint baseline and twelve hours skin samples were taken for detection time measurement. Those three layers of skin sample were taken from the same location using three different tapes. This means that the 2
nd layer was beneath the 1
st layer and the 3
rd layer was beneath the 2
nd layer.
Any skin pH measurement was performed before the 1
st layer was taken and after the 3
rd layer was taken.
Once the target site, here the arm, is ready for sampling, after the third wash, a first strip of adhesive tape is adhered to the first layer of the forearm avoiding folds. The skin site of interest can be marked in advance for consistency. To keep uniform pressure and reach optimal adhesive bond, a roller can be used to press the tape onto the skin surface (ex. twice on each site) . Then, the tapes were peeled off from the skin and placed on the surface of a TSA agar plate with the skin sample side up. The tape strips can also be inoculated prior to being placed on the TSA agar plate. Then, another strip of adhesive tape is adhered at the same location to the second layer and the second tape strip is proceed like above. Finally, another strip of adhesive tape is adhered at the same location to the third layer and the third tape strip is proceed like above.
Data analysis for detection time:
The detection time was measured for each subject at each timepoint (baseline and 12 hours) . In the first step, detection time was calculated by subtraction of the blank tape of baseline and 12 hours, by skin tape detection time at baseline and 12 hours, respectively. This is to normalize the bacteria difference at 12 hours and baseline. In the second step, mean delta detection time is calculated by subtraction of baseline by 12 hours. Finally, the delta [delta detection time] value was calculated by the difference between the two testing legs.
Skin pH measurement
The following Skin pH meter -HI 99181 with HI1414 probe (Hanna instruments) has been used.
Start-up:
1. Carefully remove the protective cap. Gently wash the end of the probe with distilled water.
2. Store the probe in distilled water between measurements.
Calibration:
The following calibration needs to be done at the beginning of each testing day.
1. Turn on the pH probe with the switch at the top.
2. Open a pH 4.01 packet and place the pH probe in the bag.
3. Hold the probe in the solution until the reading stabilizes (approx. 1 min) .
4. Using the small screwdriver, adjust the small “4/10” screw until the readout says 4.01.
5. Rinse the probe in distilled water.
6. Open a pH 7.01 packet and place the pH probe in the bag.
7. Hold the probe in the solution until the reading stabilizes (approx. 1 min) .
8. Using the small screwdriver, adjust the small “7” screw until the readout says 7.01.
9. Rinse and store the probe in distilled water.
Subject Measurement:
For a single skin layer test after recording the timepoint zero hour, any skin pH measurement was performed before any strip of adhesive tape is adhered to the single skin layer.
For a multiple skin layer test after recording the timepoint 12 hours, any skin pH measurement was performed before any strip of adhesive tape is adhered to the 1
st layer was taken and after the 3
rd layer was taken.
1. To take a measurement, remove the probe from the distilled water, leaving the end of the probe damp.
2. Place vertically on the skin area to be measured.
3. Wait for the measurement to stabilize (10-20 sec) .
4. Record the value displayed to one decimal place. (e.g., “5.2” )
5. Return probe to the distilled water between measurements.
Product pH Measurement
First, calibrate the Thermo Scientific Orion 320 pH meter. Do this by turning on the pH meter and waiting for 30 seconds. Then, take the electrode out of the storage solution, rinse the electrode with distilled water, and carefully wipe the electrode with a scientific cleaning wipe, such as a
Submerse the electrode in the pH 7 buffer and press the calibrate button. Wait until the pH icon stops flashing and press the calibrate button a second time. Rinse the electrode with distilled water and carefully wipe the electrode with a scientific cleaning wipe. Then submerse the electrode into the pH 4 buffer and wait until the pH icon stops flashing and press the measure button. Rinse the electrode with distilled water and carefully wipe with a scientific cleaning wipe. Now the pH meter is calibrated and can be used to test the pH of a solution.
EXAMPLES
The following examples further describe and demonstrate embodiments within the scope of the present invention. The examples are given solely for the purpose of illustration and are not to be construed as limitations of the present invention, as many variations thereof are possible without departing from the spirit and scope of the invention. Where applicable, ingredients are identified by chemical or CTFA name, or otherwise defined below.
The following examples were prepared:
Compositions (wt. %)
Definitions of Components
*1 Sodium laureth (1) sulfate; Supplier Procter &Gamble Co.
*2 Sodium lauroyl sarcosinate; Supplier Tinci
*3 Sodium cocoyl alaninate; Supplier Tinci
*4 Cocamidopropyl Betaine; Supplier Tinci
*5 2-pyrrolidone-5-carboxylic acid; Supplier Longteng
*6 Malic acid; Supplier Merck Sigma-Aldrich
*7 Sodium benzoate; Supplier Wuhan Youji Industries
*8 Citric acid powder; Supplier Yixing Union Biochemical
*9 EDTA (Disodium Ethylene Diamine Tetraacetic Acid) ; Supplier Shijiazhuang Jackchem Co
*10 Sodium chloride; Supplier China Salt Dongxing
q.s.: sufficient quantity
Results:
Example 2 has been compared to Comparative Example 1 which does not comprise any organic acid having a pKa greater than 2.7 such as 2-pyrrolidone-5-carboxylic acid.
Delta detection time (zero hour -baseline) | |
Comp. Ex. 1 (no PCA) | 1.93 |
Ex. 2 (with PCA) | 2.33 |
Delta [Delta detection time (C. Ex. 1 –Ex. 2) ] | -0.4 |
The Delta detection time increased for Ex. 2 versus Comp. Ex. 1. Hence, the addition of 0.1%PCA can help to improve the natural antimicrobial defensive ability of human skin or, in other words the skin natural defense efficacy against bacteria such as Staphylococcus aureus.
Skin surface pH contributes to the skin natural antimicrobial barrier. If the acid mantel of the skin is damaged/impaired, natural skin protection function will be impacted. A decrease of the Delta skin pH for Ex. 2 compared to Comp. Ex. 1 means that the skin pH has been protected, maintained and better restored to the natural skin pH after using the personal cleansing composition of Ex. 2 compared to Comp. Ex. 1. The addition of an organic acid having a pKa greater than 2.7 such as 2-pyrrolidone-5-carboxylic acid can help for restoring to the natural skin pH.
Example 2 has been compared to Example 1. The two examples differs from the pH of the personal cleansing composition.
Delta detection time (zero hour -baseline) | |
Ex. 2 (pH is 5.7) | 2.03 |
Ex. 1 (pH is 5.0) | 2.38 |
Delta [Delta detection time (Ex. 2 –Ex. 1) ] | -0.35 |
The Delta detection time increased for Ex. 1 versus Ex. 2. Hence, a pH from 5.0 to 6.5, most preferably from 5.0 to 5.5 can help to improve the natural antimicrobial defensive ability of human skin or, in other words the skin natural defense efficacy against bacteria such as Staphylococcus aureus.
Delta skin pH (zero hour -baseline) | |
Ex. 2 (pH is 5.7) | 2.51 |
Ex. 1 (pH is 5.0) | 2.28 |
Delta [Delta skin pH (Ex. 2 –Ex. 1) ] | 0.23 |
Skin surface pH contributes to the skin natural antimicrobial barrier. If the acid mantel of the skin is damaged/impaired, natural skin protection function will be impacted. A decrease of the Delta skin pH of Ex. 1 versus Ex. 2 means that the skin pH has been protected, maintained and better restored to the natural skin pH after using the personal cleansing composition of Ex. 1 (pH is 5.0) compared to Ex. 2 (pH is 5.7) . The pH of the personal cleansing composition of 5.0 can help for restoring the natural skin pH over a pH of the personal cleansing composition of 5.7.
Multiple layers test has been performed to compare Ex. 1 comprising 0.1 wt. %of an organic acid having a pKa greater than 2.7 such as 2-pyrrolidone-5-carboxylic acid at a pH of 5.0 to a commercially available cleanser: Lux Fine Fragrance Body Wash.
Lux Fine Fragrance Body Wash is available via the Database GNPD [Online] Mintel; July 2019 (2019-07) “Lux Fine Fragrance Shining Icy Cool Refreshing Body Wash” , Database accession no. 6740059: https: //www. gnpd. com/sinatra/recordpage/6740059/
Lux Fine Fragrance Shining Icy Cool Refreshing Body Wash comprises the following list of ingredients: water, myristic acid, lauric acid, potassium hydroxide, potassium chloride, sodium laureth sulfate, palmitic acid, propylene glycol, fragrance, ethylene glycol distearate, cocamidopropyl betaine, phenoxyethanol, menthol, hydroxypropyl methylcellulose, tetrasodium EDTA, butylated hydroxytoluene, piroctone olamine, manicouagan clay, Cananga odorata (ylang ylang) flower oil, CI 74160, CI 51319.
The measured pH of Lux Fine Fragrance Shining Icy Cool Refreshing Body Wash was 9.21 according to the Product pH Measurement test method as set out herein.
Thus, Lux Fine Fragrance Shining Icy Cool Refreshing Body Wash comprises at least: sodium laureth sulfate and the following organic acids: myristic acid, lauric acid, palmitic acid.
In each skin layer, the Delta detection time increased for Ex. 1 versus Comp. Ex. A -commercially available cleanser: Lux Fine Fragrance Body Wash. Hence, a personal cleansing composition as recited in the claims can help to improve the natural antimicrobial defensive ability of human skin or, in other words the skin natural defense efficacy. It is believed that an organic acid having a specific pKa greater than about 2.7, such as 2-pyrrolidone-5-carboxylic acid at a pH of 5.0 over a pH of 9.2 can penetrate at least three layers into the skin, which can provide a deep layer of protection to users for at least about 12 hours.
The pH value was calculated based on the same procedure described above
Skin surface pH contributes to the skin natural antimicrobial barrier. A decrease of the Delta skin pH at each layer for Ex. 1 versus C. Ex. A means that the skin pH has been protected, maintained and better restored to the natural skin pH.
The personal cleansing composition of Ex. 1 can help for restoring the natural skin pH compared to Comp. Ex. A (Lux Fine Fragrance Body Wash) .
Effect of the anionic surfactant:
Example 2 (sodium lauryl ether (1) sulfate) has been compared to Example 3 in which the anionic surfactant now comprises a mixture of sodium lauryl ether (1) sulfate with sodium lauroyl sarcosinate as the anionic amino acid surfactant.
Delta detection time (zero hour -baseline) | |
Ex. 3 (SLE1S + sodium lauroyl sarcosinate) | 2.36 |
Ex. 2 (sodium lauryl ether (1) sulfate) | 2.08 |
Delta [Delta detection time (Ex. 3 –Ex. 2) ] | 0.28 |
Example 2 (sodium lauryl ether (1) sulfate) has been compared to Example 5 in which the anionic surfactant now comprises a mixture of sodium lauryl ether (1) sulfate with sodium cocoyl alaninate as the anionic amino acid surfactant.
Delta detection time (zero hour -baseline) | |
Ex. 5 (SLE1S + sodium cocoyl alaninate) | 2.90 |
Ex. 2 (sodium lauryl ether (1) sulfate) | 2.23 |
Delta [Delta detection time (Ex. 5 –Ex. 2) ] | 0.67 |
The Delta detection time increased for Ex. 3 or Ex. 5 versus Ex. 2. Hence, the addition of an anionic amino acid surfactant such as sodium lauroyl sarcosinate or sodium cocoyl alaninate can help to improve the natural antimicrobial defensive ability of human skin or, in other words the skin natural defense efficacy.
[Rectified under Rule 91, 21.02.2023]
The Delta skin pH decreases when the skin is treated with the composition of Ex. 3 or Ex. 5 versus Ex. 2. Hence, the addition of an anionic amino acid surfactant such as sodium lauroyl sarcosinate or sodium cocoyl alaninate can help to protect, maintain and better restore the
natural skin pH
The Delta skin pH decreases when the skin is treated with the composition of Ex. 3 or Ex. 5 versus Ex. 2. Hence, the addition of an anionic amino acid surfactant such as sodium lauroyl sarcosinate or sodium cocoyl alaninate can help to protect, maintain and better restore the
natural skin pH
Additional examples/combinations
A. A personal cleansing composition comprising:
(a) from 1%to 15%of an anionic surfactant by weight of the composition, wherein the anionic surfactant comprises sodium laureth (n) sulfate SLEnS, wherein n is the average moles of ethoxylation, wherein n equals to 1, 2 or 3;
(b) from 0.01%to 1%of an organic acid having a pKa greater than 2.7, preferably a pKa from 2.75 to 5, more preferably a pKa from 3 to 4.5, or a cosmetically acceptable salt thereof, or a mixture thereof, by weight of the composition; and
wherein the pH of the personal cleansing composition is from 5.0 to 6.5.
B. Use of the personal cleansing composition as set out hereinbefore for maintaining or improving the natural antimicrobial defense ability of human skin, preferably against Staphylococcus aureus.
C. A non-therapeutic method for maintaining or improving the natural antimicrobial defense ability of human skin against bacteria, preferably against Staphylococcus aureus, comprising the step of applying onto the human skin the personal cleansing composition as set out hereinbefore, following by rinsing off the composition.
D. Use of the personal cleansing composition as set out hereinbefore for promoting the skin natural defense efficacy, preferably against Staphylococcus aureus.
E. A non-therapeutic method for promoting the skin natural defense efficacy against bacteria, preferably against Staphylococcus aureus, comprising the step of applying onto the human skin the personal cleansing composition as set out hereinbefore, following by rinsing off the composition.
F. Use of the personal cleansing composition as set out hereinbefore for maintaining or restoring the natural skin pH.
G. A method for maintaining or restoring the natural skin pH comprising the step of applying onto the human skin the personal cleansing composition as set out hereinbefore, following by rinsing off the composition.
H. A personal cleansing composition comprising:
(a) from 1%to 15%of an anionic surfactant by weight of the composition, wherein the anionic surfactant comprises sodium laureth (n) sulfate SLEnS, wherein n is the average moles of ethoxylation, wherein n equals to 1, 2 or 3;
(b) from 0.01%to 1%of an organic acid having a pKa greater than 2.7, preferably a pKa from 2.75 to 5, more preferably a pKa from 3 to 4.5, or a cosmetically acceptable salt thereof, or a mixture thereof, by weight of the composition; and
wherein the pH of the personal cleansing composition is from 5.0 to 6.5; for use in a method of maintaining or improving the natural antimicrobial defense ability of human skin against bacteria, preferably against Staphylococcus aureus.
I. A personal cleansing composition comprising:
(a) from 1%to 15%of an anionic surfactant by weight of the composition, wherein the anionic surfactant comprises sodium laureth (n) sulfate SLEnS, wherein n is the average moles of ethoxylation, wherein n equals to 1, 2 or 3;
(b) from 0.01%to 1%of an organic acid having a pKa greater than 2.7, preferably a pKa from 2.75 to 5, more preferably a pKa from 3 to 4.5, or a cosmetically acceptable salt thereof, or a mixture thereof, by weight of the composition; and
wherein the pH of the personal cleansing composition is from 5.0 to 6.5; in a method of maintaining or improving the natural antimicrobial defense ability of human skin against bacteria, preferably against Staphylococcus aureus; characterized in that the personal cleansing composition is applied onto the human skin following by rinsing off the composition.
The dimensions and values disclosed herein are not to be understood as being strictly limited to the exact numerical values recited. Instead, unless otherwise specified, each such dimension is intended to mean both the recited value and a functionally equivalent range surrounding that value. For example, a dimension disclosed as “40 mm” is intended to mean “about 40 mm. ”
Every document cited herein, including any cross referenced or related patent or application, is hereby incorporated herein by reference in its entirety unless expressly excluded or otherwise limited. The citation of any document is not an admission that it is prior art with respect to any invention disclosed or claimed herein or that it alone, or in any combination with any other reference or references, teaches, suggests or discloses any such invention. Further, to the extent that any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition assigned to that term in this document shall govern.
While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.
Claims (15)
- A personal cleansing composition comprising:(a) from 1%to 15%of an anionic surfactant by weight of the composition, wherein the anionic surfactant comprises sodium laureth (n) sulfate SLEnS, wherein n is the average moles of ethoxylation, wherein n equals to 1, 2 or 3;(b) from 0.01%to 1%of an organic acid having a pKa greater than 2.7, preferably a pKa from 2.75 to 5, more preferably a pKa from 3 to 4.5, or a cosmetically acceptable salt thereof, or a mixture thereof, by weight of the composition; andwherein the pH of the personal cleansing composition is from 5.0 to 6.5.
- The personal cleansing composition of Claim 1, wherein the personal cleansing composition is substantially free of an antimicrobial active, preferably wherein the personal cleansing composition comprises less than 1%of an antimicrobial active, by weight of the composition, more preferably free of an antimicrobial active, most preferably wherein the personal cleansing composition comprises less than 0.1%of an antimicrobial active.
- The personal cleansing composition of any of the preceding claims, wherein the personal cleansing composition comprises from 3%to 13%of an anionic surfactant, preferably from 5%to 13%of an anionic surfactant, more preferably from 8%to 12%of an anionic surfactant, most preferably from 9%to 10%of an anionic surfactant by weight of the composition.
- The personal cleansing composition of any of the preceding claims, wherein the anionic surfactant is sodium laureth (1) sulfate SLE1S.
- The personal cleansing composition of any of the preceding claims, wherein the composition comprises from 0.5%to 10%, preferably from 0.75%to 5%, more preferably from 1%to 2%of an additional anionic surfactant, by weight of the composition.
- The personal cleansing composition of Claim 5, wherein the additional anionic surfactant is selected from the group consisting of isethionate surfactants, sarcosinate surfactants, sulfosuccinate surfactants, sulfonate surfactants, sulfoacetate surfactants, glycinate surfactants, alaninate surfactants, glutamate surfactants, lactate surfactants, lactylate surfactants, glucose carboxylate surfactants, taurate surfactants, and mixtures thereof, preferably wherein the additional anionic surfactant is selected from the group consisting of sodium cocoyl alaninate, sodium lauroyl sarcosinate, sodium cocoyl sarcosinate, and mixtures thereof.
- The personal cleansing composition of any of the preceding claims, wherein the personal cleansing composition comprises from 1%to 15%of one or more cosurfactants, preferably from 1.5%to 5%of one or more cosurfactants, more preferably from 1.5%to 2%of one or more cosurfactants by weight of the composition.
- The personal cleansing composition of Claim 7, wherein the one or more cosurfactants are selected from the group consisting of amphoteric surfactants, zwitterionic surfactants, and mixtures thereof.
- The personal cleansing composition of any one of claims 7 to 8, wherein the one or more cosurfactants comprise a zwitterionic surfactant, preferably a betaine and/or a sultaine, more preferably a zwitterionic surfactant selected from the group consisting of cocamidopropyl betaine, lauramidopropyl betaine, cocamidopropyl hydroxysultaine and mixtures thereof, even more preferably cocamidopropyl hydroxysultaine or cocamidopropyl betaine.
- The personal cleansing composition of any of the preceding claims, wherein the organic acid is selected from the group consisting of 2-pyrrolidone-5-carboxylic acid, adipic acid, gluconolactone acid, glutamic acid, glycolic acid, glutaric acid, tartaric acid, ascorbic acid, benzoic acid, salicylic acid, malic acid, succinic acid, lactic acid, a cosmetically acceptable salt thereof, and mixtures thereof; preferably wherein the organic acid is selected from the group consisting of 2-pyrrolidone-5-carboxylic acid, adipic acid, gluconic acid, glycolic acid, glutaric acid, malic acid, succinic acid, lactic acid, a cosmetically acceptable salt thereof, and mixtures thereof; more preferably wherein the organic acid comprises 2-pyrrolidone-5-carboxylic acid, or a cosmetically acceptable salt thereof, or a mixture thereof.
- The personal cleansing composition of any of the preceding claims, wherein the composition comprises from 0.02%to 0.8%, preferably from 0.03%to 0.5%, more preferably from 0.05%to 0.3%, most preferably from 0.05%to 0.15%of 2-pyrrolidone-5-carboxylic acid by weight of the composition.
- The personal cleansing composition of any of the preceding claims, wherein the pH is from 5.0 to 6.0, preferably from 5.2 to 6.0, more preferably from 5.3 to 5.8, even more preferably from 5.4 to 5.8, most preferably 5.5 to 5.7.
- The personal cleansing composition of any of the preceding claims, wherein the personal cleansing composition is in the form of a shower or bath cream, a body wash or foaming body wash, gel, emulsion, oil, mousse or spray.
- A non-therapeutic method for maintaining or improving the natural antimicrobial defense ability of human skin against bacteria, preferably against Staphylococcus aureus, comprising the step of applying onto the human skin the personal cleansing composition of any one of claims 1 to 13, following by rinsing off the composition.
- Use of the personal cleansing composition of any one of claims 1 to 13 for maintaining or restoring the natural skin pH.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2021/127315 WO2023070501A1 (en) | 2021-10-29 | 2021-10-29 | Personal cleansing composition with an organic acid having a pka greater than 2.7 |
CA3232109A CA3232109A1 (en) | 2021-10-29 | 2021-10-29 | Personal cleansing composition with an organic acid having a pka greater than 2.7 |
US17/975,668 US20230135226A1 (en) | 2021-10-29 | 2022-10-28 | Personal cleansing composition with an organic acid having a pka greater than 2.7 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2021/127315 WO2023070501A1 (en) | 2021-10-29 | 2021-10-29 | Personal cleansing composition with an organic acid having a pka greater than 2.7 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023070501A1 true WO2023070501A1 (en) | 2023-05-04 |
Family
ID=78770296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/127315 WO2023070501A1 (en) | 2021-10-29 | 2021-10-29 | Personal cleansing composition with an organic acid having a pka greater than 2.7 |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA3232109A1 (en) |
WO (1) | WO2023070501A1 (en) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2438091A (en) | 1943-09-06 | 1948-03-16 | American Cyanamid Co | Aspartic acid esters and their preparation |
US2528378A (en) | 1947-09-20 | 1950-10-31 | John J Mccabe Jr | Metal salts of substituted quaternary hydroxy cycloimidinic acid metal alcoholates and process for preparation of same |
US2658072A (en) | 1951-05-17 | 1953-11-03 | Monsanto Chemicals | Process of preparing amine sulfonates and products obtained thereof |
US5104646A (en) | 1989-08-07 | 1992-04-14 | The Procter & Gamble Company | Vehicle systems for use in cosmetic compositions |
US5106609A (en) | 1990-05-01 | 1992-04-21 | The Procter & Gamble Company | Vehicle systems for use in cosmetic compositions |
EP2090291A1 (en) * | 2008-02-14 | 2009-08-19 | KPSS-Kao Professional Salon Services GmbH | Composition for hair comprising PCA and PCA ester |
US20130172415A1 (en) * | 2011-12-29 | 2013-07-04 | Rubbermaid Commercial Products/Us | Triclosan-free antibacterial soap |
WO2015058942A1 (en) * | 2013-10-25 | 2015-04-30 | Unilever N.V. | A liquid disinfecting composition |
WO2017055789A2 (en) * | 2015-10-01 | 2017-04-06 | Reckitt Benckiser Llc | Personal cleansing compositions and methods of stabilizing the microbiome |
EP3329904A1 (en) * | 2016-12-05 | 2018-06-06 | Kao Germany GmbH | Cosmetic composition for enhancing properties of pre-colored keratin fibers |
US20200046623A1 (en) | 2018-08-10 | 2020-02-13 | The Procter & Gamble Company | Rinse-off cleansing compositions |
CN112206176A (en) * | 2020-10-14 | 2021-01-12 | 武汉赛锐希斯科技有限公司 | Bath cream for daily maintenance of psoriasis and seborrheic dermatitis skin |
-
2021
- 2021-10-29 WO PCT/CN2021/127315 patent/WO2023070501A1/en active Application Filing
- 2021-10-29 CA CA3232109A patent/CA3232109A1/en active Pending
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2438091A (en) | 1943-09-06 | 1948-03-16 | American Cyanamid Co | Aspartic acid esters and their preparation |
US2528378A (en) | 1947-09-20 | 1950-10-31 | John J Mccabe Jr | Metal salts of substituted quaternary hydroxy cycloimidinic acid metal alcoholates and process for preparation of same |
US2658072A (en) | 1951-05-17 | 1953-11-03 | Monsanto Chemicals | Process of preparing amine sulfonates and products obtained thereof |
US5104646A (en) | 1989-08-07 | 1992-04-14 | The Procter & Gamble Company | Vehicle systems for use in cosmetic compositions |
US5106609A (en) | 1990-05-01 | 1992-04-21 | The Procter & Gamble Company | Vehicle systems for use in cosmetic compositions |
EP2090291A1 (en) * | 2008-02-14 | 2009-08-19 | KPSS-Kao Professional Salon Services GmbH | Composition for hair comprising PCA and PCA ester |
US20130172415A1 (en) * | 2011-12-29 | 2013-07-04 | Rubbermaid Commercial Products/Us | Triclosan-free antibacterial soap |
WO2015058942A1 (en) * | 2013-10-25 | 2015-04-30 | Unilever N.V. | A liquid disinfecting composition |
WO2017055789A2 (en) * | 2015-10-01 | 2017-04-06 | Reckitt Benckiser Llc | Personal cleansing compositions and methods of stabilizing the microbiome |
EP3329904A1 (en) * | 2016-12-05 | 2018-06-06 | Kao Germany GmbH | Cosmetic composition for enhancing properties of pre-colored keratin fibers |
US20200046623A1 (en) | 2018-08-10 | 2020-02-13 | The Procter & Gamble Company | Rinse-off cleansing compositions |
CN112206176A (en) * | 2020-10-14 | 2021-01-12 | 武汉赛锐希斯科技有限公司 | Bath cream for daily maintenance of psoriasis and seborrheic dermatitis skin |
Non-Patent Citations (3)
Title |
---|
"The CTFA Cosmetic Ingredient Handbook", 2004, COSMETIC, TOILETRY, AND FRAGRANCE ASSOCIATION, INC. |
DATABASE GNPD [online] MINTEL; 20 August 2020 (2020-08-20), ANONYMOUS: "Pure Freesia Amino Acid Antibacterial Bath Essence", XP055910607, retrieved from https://www.gnpd.com/sinatra/recordpage/8044407/ Database accession no. 8044407 * |
LAMBERS H ET AL: "Natural skin surface pH is on average below 5, which is beneficial for its resident flora", INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL, vol. 28, no. 5, 19 September 2006 (2006-09-19), pages 359 - 370, XP071469301, ISSN: 0142-5463, DOI: 10.1111/J.1467-2494.2006.00344.X * |
Also Published As
Publication number | Publication date |
---|---|
CA3232109A1 (en) | 2023-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2725999C2 (en) | Compositions containing zwitterionic alkyl alkanoylamides and/or alkyl alkanoates | |
US11129785B2 (en) | Rinse-off cleansing compositions | |
HUT76537A (en) | Mild antimicrobial liquid cleansing formulations | |
MX2008002686A (en) | Moisturizing compositions. | |
JP2007277227A (en) | Azole-based antifungal agent-formulated cleaning composition | |
JP2013249263A (en) | Gallotannin-containing composition | |
US20210275419A1 (en) | Personal Care Compositions | |
WO2017042748A1 (en) | Moisturizing cosmetic composition | |
US20140005131A1 (en) | Active ingredient combinations of glucosyl glycerides and one or more preservatives | |
WO2023070501A1 (en) | Personal cleansing composition with an organic acid having a pka greater than 2.7 | |
WO2023070503A1 (en) | Non-therapeutic method for helping human skin maintain its natural defensive ability against bacteria | |
US20230135226A1 (en) | Personal cleansing composition with an organic acid having a pka greater than 2.7 | |
MXPA01010564A (en) | Skin cleaning method for eliminating comedones and scales from parts of the skin subjected to the proliferation of candida albicans. | |
CN118055752A (en) | Personal cleansing compositions containing organic acids having pKa greater than 2.7 | |
EP4126252B1 (en) | Compositions comprising naturally derived preservatives | |
CN118043026A (en) | Non-therapeutic method for helping human skin maintain its natural defenses against bacteria | |
US20230014524A1 (en) | Cleansing composition with pyrrolidone carboxylic acid | |
US20200360253A1 (en) | Preservative System | |
JP2003012446A (en) | Composition containing extract of plant of family portulacaceae and having reduced irritation | |
RU2806238C2 (en) | Preservation systems and compositions containing them | |
US20230372219A1 (en) | Antibacterial cleansing composition, uses and methods | |
CA3201291A1 (en) | Azoxystrobin efficacy in scalp health | |
JP2023552431A (en) | Superior effects of azoxystrobin and other strobilurin compounds | |
KR20240046528A (en) | Preservatives for cosmetic and pharmaceutical compositions | |
JP2016222736A (en) | Gallotannin-containing composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21814671 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3232109 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112024008290 Country of ref document: BR |